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ABSTRACT  
 
Type 1 diabetes is a chronic autoimmune disease characterized by cellular-
mediated destruction of the β-cells of the pancreas, leading to absolute insulin 
deficiency and consequently an aberrant glucose homeostasis. Over the past 
fifty years a global pandemic of type 1 diabetes has been registered. The global 
increase in the disease rate cannot be explained only by genetic alterations or 
improved diagnostic tools, and thus it was postulated that environmental 
factors are likely to be involved in this global trend.  
The intestinal environment, especially its resident flora and its associated 
immune system have been implicated in the pathogenesis of the disease. The 
present study aimed to characterize the intestinal environment in the most 
widely used animal model of the disease, the non-obese diabetic (NOD) mouse. 
The gut permeability and gut immune system was assessed in four populations 
of mice: three-week-old NOD mice, eight-week-old NOD mice, NOD mice with 
recent onset of the disease (progressor) and long-term non-progressor NOD 
mice.  
We demonstrated an increase in CD4+CD25+Foxp3+ regulatory T cells in the 
pancreatic draining lymph nodes and Peyer’s patches of non-progressor mice 
compared to progressor mice. We found that intestinal lymphocyte populations 
complete their development between the 3 rd and 8th week of life in the NOD 
mice. However, we could not find any significant differences between 
progressor and non-progressor NOD mice in the intraepithelial and lamina 
propria lymphocytes in small and large intestine.  
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TYPE 1  DI ABETES  AND THE GU T:   
A NEW P ATHO GENIC HYPOTHES IS 
 
 
1.1   CLIN ICA L AN D EPIDEM IOLOG ICAL  ASP EC TS O F TYP E 1  DIA B ET ES  
Type 1 diabetes (T1D), previously defined as insulin-dependent or juvenile-
onset diabetes, is a chronic autoimmune disease characterized by cellular-
mediated destruction of the insulin-secreting β-cells of the pancreas, leading to 
absolute insulin deficiency and consequently an aberrant glucose homeostasis1. 
It has been estimated that more than 20 million patients are affected 
worldwide2, representing about 5-10% of people affected by diabetes mellitus 
(DM)1. The prevalence of the disease varies geographically from <5 individuals 
per 100,000 in Eastern countries to as many as 39.9 in 100,000 individuals in 
Western countries3.A ‚North-South gradient‛ has also been described: northern 
regions have a higher incidence of the disease. Over the past fifty years a global 
pandemic of TD1 has been registered and the incidence of the disease in Europe 
is expected to double in the period 2005-2020, especially in children under the 
age of 53,4.The peak incidence of disease onset is between 6 and 15 years of age, 
the disease, however ,can also occur after adolescence, and is defined as Latent 
Autoimmune Diabetes of Adults (LADA)5.  
The clinical presentation varies, most patients having signs and symptoms of 
hyperglycemia and insulin deficiency (such as weight loss, polyuria, 
polydipsia, visual changes). This alteration of glycemic homeostasis can lead to 
keto-acidotic coma, a life-threatening complication characterized by severe 
dehydration due to osmotic diuresis and metabolic acidosis induced by ketone 
1 
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body production. Some patients, however, are identified on blood and urine 
tests before symptoms’ appearance5. Symptoms are evident only when more 
than 80% of the β-cell mass5 has been destroyed. After metabolic stabilization, 
many patients enter a clinical ‘honeymoon’, in which time insulin secretion 
improves, and some patients can even discontinue the use of exogenous insulin. 
This period is invariably followed by a definitive loss of insulin production, due 
to the complete destruction of endocrine β-cells by the autoimmune process. 
Replacement with exogenous insulin and dietary regulation are still the only 
available treatment5. Diabetic patients on replacement therapy, even under 
good glycemic control, have a substantially increased risk of premature death 
compared to the general population. Excess mortality in diabetic patients 
younger than 30 years of age is largely explained by acute complications of 
diabetes, including diabetic keto-acidosis and hypoglycemia, while adult 
patients have a doubled risk of death from cardiovascular causes than general 
population6. These data clearly highlight the need for a curative treatment for 
T1D. Despite the steady increase of knowledge about the pathogenesis of the 
disease over the last 40 years, this goal appears still far from reached. In the 
next section I will summarize our present knowledge of the pathogenesis of the 
disease. 
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1.2  THE PA THOG EN ESIS  OF  AUTO IM MUN E DIAB ET ES :  AN HISTORICAL  
OVERVIEW  AN D C URRENT  KNOW L EDG E 
The recognition of an etiological heterogeneity of diabetes has been a long 
process7,8. After the early description of a fat and a thin diabetes by Lascaux in 
1880, clinicians started classifying patients in insulin deficient and insulin 
insensitive, only in the 1930s with the introduction of insulin therapy. The terms 
type 1 and type 2 diabetes were first proposed by Dupertuis in 1944 in a study 
on the body constitution of a cohort of patients and further developed by Lister 
in 1951. He described the existence of ‚two broad groups of diabetics—the young, 
thin, non-arteriosclerotic group with normal blood pressure and usually an acute onset 
to the disease, and the older, obese, arteriosclerotic group with hypertension and usually 
an insidious onset‛7. These observations were interpreted in the light of the 
paradigm dominant at the time: diabetes was seen as a Mendelian inherited 
disease, where the putative gene was present in the homozygous condition in 
early onset patients and in the heterozygous condition in later-onset cases. 
Many attempts to establish the exact mechanisms of inheritance of the disease 
failed, leading to the definition of diabetes mellitus as ‚a Geneticist’s 
Nightmare‛79. 
In 1957 the pioneering studies from Witebsky and Rose demonstrated the 
possibility to generate autoantibodies against thyroid tissue injecting rabbits 
with their own thyroid tissue together with adjuvant10, leading in few years to 
the recognition of an autoimmune origin for different conditions such as 
Hashimoto thyroiditis and Addison’s disease. The topic gained immediate 
popularity and in 1963 the first manual on autoimmune diseases was written by 
Mackay and Burnet. By that time, however, evidence was still lacking to list 
juvenile diabetes as an autoimmune disease7. 
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T1D was acknowledged as an autoimmune disease only over the following 
decade, thanks to some observations made in different fields7: 
 The description of insulitis in a broad series of autopsies on patients 
with T1D, while this anatomic finding was previously thought to be 
uncommon11; 
• Higher levels of comorbidity with other autoimmune diseases in insulin 
deficient patients but not in non–insulin-treated ones according to 
various epidemiological studies12; 
• The demonstration of a cell-mediated autoimmunity against islet tissue 
in patients using the leukocyte migration test13; 
•  The discovery of the major histocompatibility complex (MHC) genes 
and its human homologue human leukocyte antigen (HLA). Juvenile 
diabetes was then associated with specific HLA alleles14; 
•  The identification of islet cell autoantibodies (ICAs), first in 
autoimmune polyendocrine syndromes15 then in isolated juvenile 
diabetes16; 
• The development of the first animal models of immune-mediated 
diabetes: the low-dose-streptozotocin-induced diabetic mouse17and the 
BioBreeding diabetes prone (BB-DP)rat18. A further step in diabetes 
research was the availability of a spontaneous mouse model of the 
disease, the non-obese diabetic (NOD) mouse, first described by 
Makino in 198019 
In 1976 Cudworth et al. proposed an etiological classification of diabetes 
reintroducing in modern times the terms type 1 and type 2 diabetes(T2D)20.This 
classification was later embraced by the American Diabetes Association that 
further distinguishes between autoimmune diabetes (also called Type 1a), and 
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idiopathic diabetes (also Type 1b) distinctive of people of Asian or African 
ancestry. In this thesis we will refer only to autoimmune T1D. 
In 1986 George Eisenbarth21 proposed the first comprehensive model of the 
disease (FIG. 1), which remains our reference to date, describing T1D as a 
chronic autoimmune disease and providing the framework of the progressive 
disease stages in T1D. 
 
Figure 1. Conceptual stages in the development of T1D. 
The Eisenbarth model of T1Dhas been modified in the light of new emerging data. During childhood, 
there is an increase in β-cell function (dotted line). The autoimmune process begins years before the 
clinical onset, as a result of a complex interplay between genetic, environmental and immunologic 
factors. Different antigenic epitopes are unmasked during the progression of disease. The loss of cells is 
probably not linear but may follow a remitting-relapsing scheme. Overt diabetes appears when about 
80% of β-cells are destroyed. The remaining part of the pancreas in a first phase ensures a baseline 
production of insulin (so-called “Honeymoon period”) resulting in a transient reduction of insulin 
requirement. 
(modified from Herold et al., 2013) 
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The onset of the disease appears as the consequence of multiple genetic and 
environmental factors causing the activation of an autoimmune response 
against an increasing number of β-cell antigens. This activation generates a 
strong and complex pro-inflammatory response that, in presence of an 
ineffective regulatory control of the autoimmune process, leads to chronic 
destruction of the β-cell and glycemic metabolism dysregulation22. This 
response yields to the epitope spreading process, a progressive exposure of new 
self-peptides to antigen presenting cells (APCs), that prompts the production of 
different autoantibodies against new β cell antigens such as insulin, glutamic 
acid decarboxylase (GAD), insulinoma associated protein 2 (IA-2), and zinc 
transporter 8 (ZnT8).  
Many immune cell subsets participate in the pathogenesis of the 
disease22,23(FIG. 2). Dendritic cells (DCs) are essential for the initiation of the 
immune response, acting as APCs. Macrophages play different roles in the 
development of the disease: their activation by CD4+ T cells has been described 
as an essential mechanism of β-cell killing24 and their production of IL-12 is 
crucial to promote efficient differentiation of diabetogenic CD8+cytotoxic T 
lymphocytes23. Macrophage function, however, is defective in NOD mice, 
resulting in an excess of cellular debris that potentially enhances the 
autoimmune reaction25. Both CD4+ and CD8+ T cells are necessary for the 
development of T1D. CD8+ T cells act as cytotoxic effectors using perforin and 
granzyme rather than Fas–FasL-mediated apoptotic cell death26. CD4+ T helper 
cells activate both DCs and macrophages promoting the initiation and 
progression of the disease. B cells are also necessary for the development of the 
disease in the NOD mouse both through antibodies production and acting as 
APCs, their depletion has been shown to prevent and reverse diabetes in the 
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NOD mouse27.The role for NK cells in T1D is still not clarified and discordant 
reports on their role in T1D have been published22.  
Concerning immune system regulatory functions, Forkhead box 
transcription factor 3 (Foxp3)-expressing regulatory T cells (Tregs) are primary 
controllers of immune responsiveness and peripheral immunological tolerance. 
Tregs use several regulatory mechanisms such as the production of 
immunosuppressive cytokines like IL-10 and TGF-β, competition for IL-2 and 
killing of APCs through release of cytotoxic granules22. Their immune-
regulating role has been confirmed in different experimental settings in the 
NOD mouse and there is also evidence of their involvement in the onset of the 
human disease28,29. Tolerogenic DCs, induced by immunomodulatory 
treatments such as cyclosporine, tacrolimus, rapamycin, mycophenolate 
mofetil, corticosteroids and vitamin D22,23,30, are able to efficiently prevent T-cell 
activation. Tolerogenic DCs have been showed to promote proliferation and 
differentiation of Tregs, but also to prevent activation of naive CD8+ T cells and 
induce depletion of memory CD8+ T cells. Administration of tolerogenic DCs 
can protect mice from developing diabetes and prevent rejection of grafted 
islets22. A protective role in the development of the disease has also been 
proposed for invariant NKT cells23. 
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Figure 2. Immune mechanisms involved in β-cell destruction 
DCs can process β-cell antigens released after apoptosis or infection. IFN ac tivates DCs and promote 
presentation of βcell antigens to T cells.  The DCs can activate CD4+ T cells, which trigger macrophage-
mediated killing and also activate islet antigen-specific B inducing their differentiation into antibody-producing 
plasma cells. Antibodies can bind βcells and mediate complement killing as well as binding to Fc receptors on 
macrophages. Activated B cells can also function as APCs. Cytolytic CD8+ T cells (CTLs) kill β-cells through 
perforin and granzy mes, as well as through Fas–FasL interaction. Regu latory cell subsets such as IL-4-
producing NKT and Foxp3+Tregs cells can stop the progression of the immune attack. IL-21 produced by 
CD4+ cells can inhibit Tregs. 
(modified from Wållberg and Cooke, 2013) 
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Recent insights into the autoimmune process in T1D have fostered several 
immune modulation strategies based on systemic or antigen-specific 
interventions (FIG. 3)2,5,22,31. Systemic approaches aim to treat the disease by 
depletion of adaptive immune cells (e.g. cyclosporine A, anti-CD3, Rituximab, 
Abatacept etc.), interventions in cytokine pathways (e.g. Anakinra, Etanercept), 
systemic immunomodulation (e.g. vitamin D, rapamycin and IL2, HSP60) or 
autologous bone marrow transplant. Antigen-based strategies aim to elicit 
immune tolerance by exposing the immune system to insulin or other β-cell-
antigens via different routes (enteral, parenteral, subcutaneous, intranasal,)5,22. 
So far none of the immunological approaches has succeeded in restoring active 
tolerance or halting autoimmunity, giving long-lasting independence of 
exogenous insulin in patients22. Some systemic interventions (e.g. cyclosporine 
A, rituximab and anti-CD3) have proved to be partially effective in 
accomplishing  clinical endpoints, but their benefit-risk balance has been 
considered unacceptable32. The antigen-based approaches have been effective in 
animal models, but all the attempts to replicate these results in patients have 
failed so far31. This situation is leading to a deep rethinking of many aspects of 
T1D research such as the choice of animal models33, the importance of setting 
accurate clinical endpoints and the discovery of new biomarkers capable of 
identifying different stages of the disease and potential remission5,31. The idea 
that T1D can comprise heterogeneous conditions has been extended, raising the 
need for more accurate patient stratification algorithms and tailored treatments 
implementation22 
Studies on the genetic and environmental susceptibility factors in general 
and high-risk populations promise to provide new data that can change the 
view of the pathogenesis of the disease and result in innovative strategies to 
prevent, delay or reverse T1D. 
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Figure 3. Results of immunotherapy trials in T1D.  
Therapies have been designed to target innate and adaptive immune responses that are thought to contribute to 
T1D pathogenesis. Some interventions have showed beneficial effects: rituximab, which depletes B cells; 
cytotoxic T  lymphocyte,CTLA4–Ig fusion protein, which blocks the delivery of CD80 and CD86 co-stimulatory 
signals to T  cells; or CD3-specific monoclonal antibodies, which deplete T  cells. Anti-thymocyte globulin with 
glucocorticoids or autologous bone marrow transplant have also been successful. These approaches, however, 
were burdened by unacceptable side effects. T herapies involving administration of autoantigens or blocking pro-
inflammatory cytokines (e.g. anti-interleukin-1 (IL-1) reagents) have not shown, so far, beneficial effects in human 
cohorts. A trial of rapamycin and IL-2 had a negative effect on patients who showed a transient decline in C 
peptide responses. A trial using treatment with heat-shock protein 60 (HSP60), which is thought to enhance 
Tregs cell functions via Toll-like receptor 2 (TLR2), has shown a beneficial effect on C peptide responses. A pilot 
trial of a soluble tumour necrosis factor (TNF) receptor (etanercept) resulted in lower blood glucose levels and 
increased insulin production in patients. 
(modified from Herold et al., 2013) 
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1.3  INT ERPLAY O F G EN ET ICS  AN D ENVIR ONM ENT  
IN TYP E 1  DIAB ET ES SUSC EPTIB IL ITY  
The relative contributions of environment and genetics in T1D are still a 
matter of debate. Recently a ‚threshold hypothesis‛34 (FIG. 4) was proposed to 
envisage the simultaneous contributions of genetics and environment in T1D. 
According to this model, it is highly unlikely that a single risk factor would be 
capable of triggering T1D. Instead, it is far more likely that specific risk factor 
combinations are the key to understand the pathogenesis of T1D34. 
The first evidence of a genetic factor in T1D came from twin studies: the risk 
for identical twins has been reported to be as low as 30%, but more recent data 
have suggested that, with a longer observation period, 65% are concordant35. 
The risk of developing T1D is 6% if a sibling is affected, while the risk is 0.4% in 
the general population5. Except from some rare mutations in key genes for the 
development of central immune tolerance, the genetic region most strongly 
associated with T1D is the HLA locus, both in the development and protection 
from the disease2,9. In particular DR3 and DR4 haplotypes confer the highest 
risk while DR2 has a strong protective role36. Other regions that show a weaker 
but significant association with the disease are genes coding for interleukin-2 
receptor (IL-2R), cytotoxic T lymphocyte antigen 4 (CTLA-4) and protein 
tyrosine phosphatase non-receptor type 22 (PTPN22) which are all primarily 
expressed in immune cells. However genes involved with insulin production 
and protection of β-cells from apoptosis have also been identified as playing a 
role in the disease9. Eventually, some polymorphism of the insulin-dependent 
diabetes mellitus 2 (IDDM2) gene, located in the proximal promoter of the 
insulin gene, have been associated with an increased risk of developing T1D. 
This gene, when mutated, lowers insulin expression in the thymus and possibly 
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hampering the development of a normal immunologic central tolerance toward 
insulin2,5,9,22. 
 
 
  
Figure 4. Nurture and nature in T1D 
Arranging odds ratios (ORs) for the development of T1D in rank order, two curves can be drawn, one for 
genetic risk (Blue) and one for environmental risk (orange). Only few genetic mutation in key genes for 
immune tolerance development dramatically increase the risk for T1D. High risk HLA haplotypes confer 
an OR of 7. The other risk genes such as INS and PTPN22 have a minor impact with an OR of about 2. 
The HLA-DBQ has a protective role making the curve dip below 1. As far as environmental factors are 
concerned pancreatectomy and exposition to β cells toxins have obviously a very high OR while the 
impact of dietary, infectious, perinatal and postnatal factors is still object of study. Vitamin D 
supplementation act as a environmental protective factor. The sum of genetic and environmental factors 
can result in passing the threshold (black dotted line) which corresponds to the development of the 
disease  
(from Wasserfall et al., 201134) 
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Genetic factors, however, cannot explain the rise in T1D that happened over 
decades, for this reason many studies have tried to clarify the role of 
environmental factors in the development of the disease. Early exposure to 
different dietary components has been implicated as a potential trigger of 
autoimmunity. In particular the response to dietary proteins contained in cow’s 
milk and cereals has been widely explored2. In the BB-DP rat model a 
50%reduction in the development of T1D was observed when BB-rats were 
weaned to an extensively hydrolyzed-casein diet instead of a whole-protein 
diet, excluding intact proteins and their potentially diabetogenic epitopes37. In 
particular cow's milk insulin has been proposed as a possible trigger of 
autoimmune response to insulin in the context of an immature mucosal 
immune system or enteric viral infections38,39. The Finnish TRIGR pilot study 
showed that hydrolyzed formula in infancy significantly reduced the 
appearance of diabetes-associated autoantibodies40, although this result was not 
confirmed in the other national cohort of this study41. Regarding cereal proteins 
are concerned, epidemiological studies suggested that there is a higher 
incidence of overt coeliac disease (CD) in patients with T1D. Besides,T1D and 
CD share overlapping HLA susceptibility loci and 2–10% of patients have 
histological evidence of gluten sensitive enteropathy; approximately 10% of 
DQ2 homozygous T1D patients have circulating IgA autoantibodies against 
tissue transglutaminase (tTG)42.The timing of exposure to gluten was linked to 
T1D development. The BABYDIAB study found that children exposed to 
gluten-containing cereals before the age of 3 months have an increased risk of 
developing islet autoantibodies, compared with children who only received 
breast milk during the same period. Children receiving gluten after the age of 6 
months did not have an increased risk of developing islet autoantibodies. The 
DAISY study found that children exposed to both non-gluten-containing and 
gluten-containing cereals before the age of 3 months or after 7 months had an 
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increased risk of islet autoimmunity compared with children first exposed to 
gluten between the ages of 4 and 6 months. Moreover, the DAISY study showed 
that if cereals were introduced while the child was still breastfed, the risk of 
developing islet antibodies was reduced43. Also fruit, berries, and vegetable 
roots have been invoked as risk factors for β-cell autoimmunity development44.  
Caesarean section may increase the risk of T1D by 20%. A recent study has 
found that children delivered by C-section with a variant in the IFIH1 gene, a 
helicase involved in sensing viral RNA and inducing the IFN response, have an 
increased risk of T1D40,45. 
The potential role of viral infections in T1D has been studied for a long time. 
This hypothesis originated from the observation of a sea sonal onset of the 
disease. Different viral strains have been proposed as possible culprits7,23. By 
now viral enteric infections are considered the most likely trigger of the disease 
in some patients40. The suggested underlying mechanisms are either molecular 
mimicry, as observed in rotavirus infections, where T cells specific for epitopes 
of rotavirus VP7 protein cross-react with antigenic epitopes of islet 
autoantigens46 or direct infection ofβ-cells, as in the case of enteroviruses47. 
Direct infection of β cells by enteroviruses could result in islet destruction and 
release of pancreatic antigens to APCs leading to immune system and chronic 
insulitis activation in predisposed patients.  
Vitamin D is one of the most promising environmental candidate for T1D 
prevention48,49. Vitamin D is synthesized in the skin from 7-dehydrocholesterol 
under the action of ultraviolet B (UVB) light. T1D is more frequent in Northern 
countries where the population is exposed to reduced levels of ultraviolet light 
and presents consequently low levels of vitamin D in utero and during 
childhood50. The mechanism of this protective action are largely unknown, but 
likely involve immunomodulation and β-cell protection40.  
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A unifying pathogenic model that explains the role of the different 
environmental factors is still lacking, but research in emerging fields such as 
mucosal immunology and microbial ecology is giving rise to new intriguing 
hypotheses. 
1.4  THE INT EST INAL  ENVIR ONM ENT:  
W HIC H ROL E IN TYP E 1 DIAB ET ES?  
 
Renewed interest in the environmental susceptibility factors of T1D was 
fueled by the new insights on the intestinal immune system and the resident 
bacterial communities in the gut (microbiota). In particular the gut has emerged 
as a potential key organ in the development of a variety of allergic and 
autoimmune conditions, including T1D. According to this model, sometimes 
called ‚the perfect storm model‛51or ‚gut model‛52,an intestinal environment 
aberrant in one of its three components (the intestinal microbiota, the gut 
permeability or the mucosal immunity, FIG. 5) can be an important risk factor in 
the development ofT1D. This hypothesis has a basis in the strict immunological 
and anatomical link between the two organs: pancreatic draining lymph nodes 
(PLNs) are strictly associated with the mesenteric lymph nodes (MLNs) and 
recirculation of lymphocytes between these districts has been demonstrated. 
Moreover it is well known that diet changes and microflora manipulation have 
a deep effect on the development of the disease in animal models. Two 
principal mechanisms have been proposed to explain this phenomenon: 
bystander activation and molecular mimicry53. 
Bystander activation refers to concomitant presentation of a self-and a 
microbial antigen (including superantigen) to antigen-specific T cells during 
tissue damage. In this context of a pro-infammatory cytokine milieu tolerogenic 
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signals that normally prevents inflammatory reactions against self-antigens can 
be overridden. Altered microflora (dysbiosis) can engender mucosal barriers 
disruptions and chronic inflammation with a switch from tolerogenic responses 
to antigens, typical of the gut immune system, to effector ones. Moreover 
microbial metabolites in a context of increased gut permeability can alter the 
differentiation and activation of different cell subsets leading to an immune 
system prone to autoimmunity. A flaw in gut environment could affect 
cytokine environment and antigen presentation modalities not only in MLNs 
but also in PLNs, potentially facilitating the development of pancreatic 
autoimmunity in predisposed subjects51,52,54. 
Some non-self-peptides can elicit an immune response against self-peptides 
by molecular mimicry or cross-reactivity. According to this hypothesis chronic 
autoimmune diseases could be triggered by cross-reactivity with colonizing 
commensals53. This mechanism has been demonstrated only for some 
autoimmune disease such as rheumatic fever, Guillain-Barré syndrome, 
uveitis55. Also food antigens, in the context of an altered flora, mucosal immune 
system and gut permeability, could elicit an autoimmune response as it 
happens in CD. The permanent colonization by cross-reacting microbes would 
induce a chronic inflammatory stimulus, renovating the autoimmune attack53. 
The gut hypothesis has the merit to shed new light on the different 
environmental factors identified by patient studies. 
Cesarean sections have been shown to deeply change the acquisition and 
structure of the initial microbiota in the newborn. At the delivery the newborn 
is sterile and acquires the maternal microbiota. Initially the microbiota is 
undifferentiated across all body habitats. Children born via Cesarean section 
will be colonized by bacteria coming from maternal skin microbiota instead of 
TYPE 1  D IA BETES  A ND  THE G UT 
 
27 
 
vaginal microbiota. This abnormal microflora could induce an immune system 
more prone to autoimmunity56. 
Enteric infections could indirectly affect the pancreas by altering the 
intestinal epithelium. This may cause a loss of barrier function resulting in 
translocation of gut microbial products which in turn can induce pancreatic 
immune activation52. 
The diet plays a pivotal role in shaping the microbiota:  the effect of food 
interventions effect may be due to the modification of the resident flora40. The 
co-morbidity of T1D and CD suggest that an aberrant immune response to 
dietary proteins, triggered by an altered mucosal immunity, could predispose 
to autoimmune reactions against pancreatic β-cells.  
Also vitamin D seems to play a role in maintaining the integrity of the 
intestinal mucosal barrier and controlling gut permeability by enhancing tight 
junction (TJ) expression57. 
A thorough analysis of the three components of intestinal environment and 
their putative role in autoimmunity and T1D will be the subject of the next 
three chapters of this introduction.  
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Figure 5. Intestinal environment and T1D 
According to the “gut hypothesis” an alteration of the gut environment could trigger diabetes in 
predisposed subject.  Altered microbiota can lead, especially in presence of other environmental 
stressors, such an enteric infection, to an increased permeability of the gut to luminal antigens. The 
consequent mucosal immunological activation, especially in subject with a constitutively altered mucosal 
immunity, can induce the secretion of pro-inflammatory cytokines further enhancing gut permeability. By 
triggering by-stander activation phenomena, this chronic inflammatory milieu can dampen regulatory T 
cell differentiation, that normally prevents autoimmunity in MLNs and PLNs, and promote Th1/Th17 
responses to self-antigens, including β-cell ones. Still uncharacterized luminal antigens may also directly 
elicit an autoimmune response via a mechanism of cross-reactivity with pancreatic antigens. 
(from Vaarala et al., 2008) 
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MICROBIOTA AND TYP E 1  DIABETES :   
CLUES  FOR A CORRELATIO N  
 
 
2.1  INT ESTINAL  M ICROB IOT A:  A N EW  ACTOR  IN  HUMAN  HEALT H  
The microbiota has been defined by the Nobel prize winner microbiologist 
Joshua Lederberg, who first proposed this concept, as ‚the ecological 
community of commensal, symbiotic and pathogenic micro-organisms that 
share our body space"58. The term microbioma, which is often used as a 
synonym, properly refers to the gene content of this community. Metagenomic 
is the discipline that studies the genetic content found in environmental 
samples, including human body surfaces. The human microbiota comprises 
diverse microbiologic ecosystems (such as gastrointestinal (GI) tract, skin, 
airways, vagina) and is composed of a variety of bacteria, archaea, micro-
eukaryotes (e.g. fungi, parasites), and viruses (eukaryotic and bacterial)59. 
Microbial communities are thought to outnumber human body somatic and 
germ cells by an estimated 10-fold and have at least 100 times as many genes as 
our own genome60,61. Although the diversity of the microbial world has been 
appreciated for decades, scientists were constrained by the inability to culture 
many bacteria in the laboratory59,61.Only recently advances in high-throughput 
sequencing technologies coupled with new bio-informatics developments have 
allowed the scientific community to begin to deeply investigate this field62. 
The intestine with its 1014 commensal bacteria forms one of the most densely 
populated microbial habitats known in biology63. Large intestine microbiota is 
the best characterized one, since its composition can be derived by the 
2 
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extraction of genetic material from human fecal samples. A common approach 
to assess microbial communities composition is the analysis of 16S rRNA gene 
sequences from bacteria. Given to their slow rates of evolution, these genes are 
useful to reconstruct bacterial phylogenies. Although 16S sequencing is the 
most widely used platform for gut microbiome studies, because of its low cost, 
it has several notable limitations64. First the 16S gene is subject to copy number 
variations. For this reason the observed proportions of 16S gene sequences 
might not reflect the proportion of the bacteria in the sample. The choice of PCR 
primers can give rise to several biases, preventing the detection of entire species 
or clades. 16S sequencing does not provide information about the genomes of 
its members nor their functions. Most importantly, 16S sequencing identifies 
only bacterial components of a community and no other types of microbes. The 
decrease in costs is facilitating the use of whole-metagenome sequencing 
(WMS), based on sequencing the entire genetic material in the sample.  This 
approach allows a higher resolution to the level of species and strains and 
provides information about its functional capabilities by combining the 
observed genes into pathways. The limitation of this approach, however, is that 
we can only assume that highly represented sequences, and metabolic 
pathways that they reveal, are meaningful. A possible solution to this could be 
the high-throughput sequencing of RNA (meta-transcriptomic analysis) that 
directly shows which genes are really expressed in the sample. This approach 
has not been widely used yet, as it requires the removal of ribosomal RNA that 
represents the majority of microbial RNA64. 
In healthy individuals, intestinal microbiota comprises more than 1000 
species of bacteria that contribute to GI homeostasis. Two principal phila, 
however, are mostly represented in man, Bacteroides and Firmicutes, making up 
99% of the total61. Bacteroides use a very wide range of substrates and are major 
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producers of short chain fatty acids(SCFAs) propionate and acetate. Firmicutes 
(such as Lactobacillus spp.) include several species that degrade indigestible 
polysaccharides and have been identified as the dominant producers of the 
SCFA butyrate, a powerful anti-inflammatory factor that improves gut barrier 
function. Actinobacteria (which includes Bifidobacterium spp.), Proteobacteria 
(which includes Escherichia coli), and Verrucomicrobia (which includes 
Akkermansia mucinophila, a mucin degrading bacterium) are typically present in 
smaller numbers in the healthy gut microbiota, but these organisms have 
considerable potential to influence health outcomes65. The microbiota in mice 
appears different especially for the high abundance of segmented filamentous 
bacteria (SFB) not present in human flora. Another important difference is that 
bacteria in rodents can directly contact the colonic wall in the proximal colon 
and enter crypts in high concentrations66. In human healthy gut the mucosal 
layer prevent direct contact between the microbes and intestinal epithelial cells 
(IECs). 
The importance of the microbial flora, often considered as a ‚forgotten 
organ‛67, in human health and disease is being increasingly investigated. In 
particular, to the well-known function of degrading undigested leftover 
producing valuable substances, such as vitamins and SCFAs, an important role 
in shaping the immune function and metabolism is now recognized to 
microbial communities. This action is mediated by a direct interaction of 
intestinal microbiota with the adjacent mucosal environment, principally 
mediated via innate immunity receptors, modulating local inflammatory 
activity and the development of several different mucosal immune system 
population. An indirect route to shape immunity is mediated by microbial 
metabolites: altering intestinal permeability metabolites produced by the 
intestinal flora can enter the submucosa and the circulation influencing immune 
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function68,69. Seen this complex cross-talk between the flora and its host many 
diseases have been proposed to be linked to dysbiosis. Autoimmune diseases, 
obesity, atherosclerosis, autism, psychiatric conditions were the most widely 
studied conditions to prove a correlation with intestinal dysbiosis. Large global 
consortia such as the US Human Microbiome Project have sought in the last 
years to provide knowledge on microbial composition in health and disease. 
This study, based on a follow up of 242 healthy patients, showed a high level of 
between-individual variation while within individual variation was relatively 
low. Microbiota stability is therefore considered a marker of healthy status. Low 
diversity of gut microbes is emerging as a risk factor for multiple metabolic and 
autoimmune disease. The composition and functional characteristics of a 
healthy microbiome, however, remain to be precisely defined70. Recently three 
enterotypes in healthy humans were described, based on the prevalence of 
phyla present in the microbiota71. Enterotypes appear to be independent of 
gender and nationality, but their function and implications of are still 
unknown70. 
2.2  MICROB IOT A IN TYP E 1  DIAB ET ES :  
LESSONS  FRO M AN IMAL  MO DELS AN D PAT IENTS  
Over the last years multiple evidence have accumulated in support of a role 
for microbiota in the pathogenesis of T1D. 
Studies from BB-DP rats and NOD mice gave the first supporting data. In 
1987 it was showed that transferring NOD mice from a pathogen free to a germ 
free environment caused an increase in diabetes incidence72. These results were 
partially confirmed by more recent studies where germ free mice showed an 
earlier development of insulitis compared to controls, although the diabetes 
incidence was not significantly different between the two groups73,74. Different 
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antibiotics (sulfamethoxazole, trimethoprim and colistin sulphate in rats75, 
doxycycline and vancomycin in mice76) were able to decrease the incidence of 
diabetes compared with controls. Metagenomic studies revealed significant 
differences in the composition of microbiota between BB-DP and BB diabetes 
resistant (BB-DR) rats: an increased proportion of Bacteroides, was present in BB-
DP rats while Lactobacillus was higher in BB-DR ones77. Single microbial agents 
were also proved to affect the development of the disease, in particular the 
presence of segmented SFB in female NOD mice is correlated with decreased 
insulitis incidence78 while in BB-DP Lactobacillus johnsonii and Lactobacillus 
reuteri respectively prevented and promoted diabetes79. NOD mice carrying a 
null mutation in an adaptor for multiple innate immune receptors, the myeloid 
differentiation primary response gene (MYD88), that normally modulates the 
crosstalk between microbiota and immune system, are protected from T1D and 
have an altered microbiome compared to wild-type controls80. The microbial 
fauna was also proposed as a possible mediator of diet influence on diabetes 
incidence in NOD mice. Alterations of microbiota and increase of diabetes 
incidence were documented after administration of a high-cereal diet81,82 and 
acidic drinking water83 in NOD mice, while a hydrolyzed casein-based diet 
resulted in an increase of beneficial gut microbiota and reduced Bacteroides72. 
The microbiota seems also involved in the typical gender bias of NOD mice. 
Normally female mice have higher incidence of T1D. Fecal transplantation from 
adult male mice to immature females prevents the disease and results in 
elevated blood testosterone84. The intestinal microbiota includes not only 
bacteria but also fungi and viruses. The interplay between these 
microorganisms regulates their growth and function and probably plays a role 
in T1D. In a model of virus-induced diabetes, Kilham rat virus infection 
resulted in a transient change in microbiota composition. Uninfected animals 
had no such modification and a treatment with a combination of trimethoprim 
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and sulfamethoxazole prevented the onset of disease and diminished Peyer’s 
patches (PP) and PLN inflammation. Conversely, poor fitness of gut microbiota 
in humans could explain why children who develop T1D are prone to 
enterovirus infections85 that tend to become chronic86. 
In humans, so far, epidemiological studies failed to find an association 
between antibiotics use and pancreatic autoimmunity87.Metagenomicstudies 
seem to confirm the data found in mice. A pilot Finnish study by Giongo et 
al.88on four T1D cases and four matched controls showed a higher level of 
Bacteroides in children who developed autoimmunity and a less diverse and less 
stable microbial flora. These results were substantially confirmed in another 
study from the same research group on 18 children randomized for HLA 
genotype, gender, early diet89. Brown and colleagues90 reanalyzed samples of 
the four subjects of the pilot study with a WMS approach finding that genes 
involved in carbohydrate metabolism, adhesions, motility, phages, prophages, 
sulfur metabolism, and stress responses were more abundant in cases. These 
data suggest that increased adhesion and flagella synthesis in autoimmune 
subjects may be involved in triggering a T1D-associated autoimmune response 
compromising gut barrier. Analysis of 16S rRNA confirmed a higher proportion 
of butyrate-producing bacteria in the control group and found few mucin-
degrading bacteria in the cases group, suggesting a reduced mucosal layer 
compared to control. The study also, suggested that the presence of both 
lactate- and butyrate-producing bacteria (lactate is converted to butyrate) in the 
healthy gut is essential to ensure mucin synthesis and maintain gut integrity. 
Bigger experiments had contrasting results. An analysis on 22 patients 
conducted in the German BABYDIET study failed to find significant differences 
in microbial composition, while further analysis showed that microbial 
communities in sick children were far less correlated each other than control 
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and much more instable91. In the Finnish DIPP study87 29 cases and 47 controls 
were analyzed during the first 4 years of life. In this population it was found 
that a large increase in one bacterial species, Bacteroides dorei, occurred 
approximately 8 months prior to the average time of appearance of the first 
autoantibody in the cases group. This study was conducted on a cohort of 
children born in the same hospital, Turku University Hospital, and all of the 
children lived within 80 km of distance from each other. This probably helped 
to reduce confounding factors present in the BABYDIET study that instead 
collected children from all over Germany. Interestingly, the only difference 
between the genomes of two strains of. Bacteroides dorei from a control and a 
child who developed T1Dwas the presence of a phage-borne DNA 
methyltransferases in the affected child. This is the first evidence of a possible 
role for phage-mediated methylation differences in the development of T1D92. 
A recent American study93from Denver metro area analyzed the microbiome 
of four populations, namely new onset patient, subjects with insulin 
autoantibodies (IAAs), sero-negative first degree relatives, and unrelated 
healthy controls. The authors found a pattern characterized by an increased 
abundance of the Bacteroidetes genus Bacteroides and a reduction in the 
Bacteroidetes genus Prevotella and the phylum Firmicutes in subjects with 
multiple autoantibodies versus subjects with one type of autoantibody. The gut 
microbiota of healthy control subjects with no family history of autoimmunity 
had increased abundances of Lactobacillus spp. and Staphylococcus spp. 
Compared with new- onset patients and sero-positive and sero-negative 
relatives. 
These findings strongly support the idea that dysbiosis is a feature of subjects 
with T1D that could play an important role in the development of the disease.  
  
PART I: BACKGROUND 
 
36 
 
GUT PERMEABILITY AND  
ITS  INFLUENCE ON TYPE 1  DI ABETES  
 
 
3.1  INT EST INAL MUC OSAL B ARRIER IN HEALT H AN D DIS EAS E  
The intestinal mucosa is the largest mucosal surface of the human body. It 
has to fulfill seemingly opposite functions: on the one hand, it acts as a 
gatekeeper defending the body from dangerous macromolecules penetration 
and pathogens, on the other hand, it has to allow nutrient absorption and 
promote peaceful co-existence with intestinal symbionts38.Intestinal 
permeability is the property that allows solute and fluid exchange between the 
lumen and tissues94,95. Intestinal barrier function refers, instead, to the ability of 
the mucosa and extracellular barrier components to prevent this exchange. 
Immune functions are often included in the concept of mucosal barrier, but in 
this chapter, however, by this term we will refer exclusively to trans-epithelial 
flux of solutes and fluids94. 
The mucosal barrier is organized in multiple anatomical and functional layers. 
The first layer from the lumen corresponds to the mucus layer, a gel principally 
produced by goblet cells’ secretions, namely mucins, trefoil peptides and 
surfactant lipids94,95.It extends up to 150 μm from the epithelial surface, forming  
two strata: the outer mucus layer, penetrable by commensal bacteria, and the 
inner layer, resistant to bacterial penetration. A zone of limited luminal flow, 
the so-called unstirred layer, directly overlies the epithelium under the mucus. 
The anatomical barrier is mainly constituted by the IEC lining. IECs acts as a 
selective blockade for hydrophilic solutes, through their lipophilic cell 
3 
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membrane and cell junctions located in the intercellular space that prevent 
paracellular transport of solutes96.Three main type of junctions are found in gut 
epithelium: adherent junctions (AJs), tight junctions (TJs), and desmosomes, 
consisting of several protein such as occludines, cadherins, claudins, and 
zonulin97. These transmembrane proteins interact with adjacent cells and with 
intracellular adaptor proteins, which are linked to the cytoskeleton97. The 
regulation of junctions, and therefore epithelial barrier permeability, is achieved 
through myosin phosphorylation and contraction of actomyosin complexes 
(FIG. 6).96,97.Permeability increases in gut permeability is promoted by different 
immune cells activations such as intraepithelial lymphocytes (IELs), mast cells 
and eosinophils98. Pro-inflammatory cytokine production, especially IFN-γ and 
TNF-α, increases intestinal permeability, while IL-10 exhibited a protective 
effect98.Zonulinrepresents, by now, the only known physiologic modulator of 
intercellular tight TJs, promoting, with its upregulation, gut permeability99. 
Many environmental factors have been related to the increase of gut 
permeability such as western-style diet, stress, alcohol, non-steroidal anti-
inflammatory drugs, alterations of microbiota, intestinal bacterial and parasitic 
infections95. A protective effect has been proposed for corticosteroids, 5-
aminosalicylic acid, Glucagon like peptide (GLP) 2 analogs, anti-TNF-α agents, 
mucosal protectors and probiotics95,98, and vitamin D57. The action of microbiota 
on gut barrier is probably mediated by SCFAs. Butyrate produced by an 
healthy microbiota, acts as a strong protector of mucosal barrier inducing the 
production of mucin and restoring TJs in the epithelial layer, while propionate 
or acetate produced by members of the genus Bacteroides increase barrier 
permeability92,95. Butyrate has also epigenetic effects on macrophages that result 
in  an anti-inflammatory and antioxidant function and on lymphocytes 
promoting regulatory differentiation92. 
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Figure 6. Cell junctions in enterocythes 
A. Enterocytes present a complex system of cell junctions, which form a structural net encompassing 
extracellular space and cytoskeleton. TJs or zonulae occludentes are found in the apical segment and are 
the main regulators of paracellular permeability. On the basolateral side of the cell other cell junctions are 
present e.g. adherents junctions and desmosome. 
B. TJs have been widely explored with electronic microscopy and from a biochemical point of view. In 
electron microscopy tight junction clearly appears as kissing points between cell membranes. The 
structural components of intercellular tight junctions can be classified in integral membrane proteins 
(occludin, claudins), junctional complex proteins (ZO-1, ZO-2, p130 or ZO-3, 7H6, symplekin, cingulin), and 
the cell cytoskeleton structures (microtubules, intermediate filaments). 
(from Fasano et al., 2012) 
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Intestinal permeability can be assessed with different methods ex vivo and in 
vivo95. Ex vivo methods are based on electrophysiology with direct measure of 
short-circuit current as indicator of an active ion transport or on the histological 
examination of gut mucosa samples. In vivo functional methods comprehend 
permeability assays. These tests usually assess fractional urinary excretion of 
orally-ingested probes. The selected probes must be unable to cross the 
epithelium via a transcellular route, any probe that enters the blood stream is 
thus assumed to have crossed the TJs or a site of epithelial damage94. Usually 
oligosaccharides of large size such as lactulose, PEG and fluorescein 
isothiocyanate (FITC)-labeled dextran are exploited. To correct absorption 
confounding factors a second assay with a low size oligosaccharide which is 
thought to freely cross the intestinal barrier, e.g. mannitol, is performed. 
Permeability is then evaluated as a ratio between the two urinary measures. 
Also biomarkers related to bacteria (e.g. LPS, bacterial lactate), epithelial 
damage (e.g. citrulline, zonulin, claudin-3), and immune activation (e.g. fecal 
calprotectin, serum IgA) have been proposed as indicators of mucosal integrity 
95,100. 
The ‚leaky gut syndrome‛ is emerging as a new important condition in the 
development of autoimmune and metabolic disease94,95,101. According to this 
model, mostly validated on CD, a fundamental step in the development of 
autoimmune disease is the loss of the protective function of mucosal barriers 
due to alterations of cell junctions. This dysfunction causes an increase of 
mucosal permeability, the passage of endoluminal dietary and microbial 
molecules into the mucosal and submucosal layer, the activation of the response 
of APCs and cytokines release that can further increase gut permeability97,101. 
This immune activation can promote, in predisposed subjects, autoimmune 
responses disrupting normal tolerance to orally delivered antigens(FIG.6).The 
PART I: BACKGROUND 
 
40 
 
entrance of microbial products, especially bacterial LPS in the portal and 
systemic circulation, produces a generalized state of innate immunity activation 
called endotoxemia, which has been associated to metabolic disease102.  
Alterations of gut permeability have been documented not only in intestinal 
disease such as inflammatory bowel diseases (IBDs), food allergy, irritable 
bowel disease and CD but also in extra-intestinal disease such as asthma, 
multiple sclerosis, ankylosing spondylitis and T1D101. 
 
 
 
  
Figure 7. Diet, microbiota and gut permeability in the development of autoimmunity 
Western style diet characterized by a high intake of fat, gluten and low resistant starch promotes an increase in 
the percentage of Bacteroides percentage in gut microbiota. This colonization causes a decrease in butyrate 
production that induces a reduced secretion of mucin and loosening of tight junctions. In this context it is easier 
for dietary antigens to enter the mucosa and bloodstream where they can elicit autoimmune responses in 
predisposed subjects. A diet with low fat, low gluten and high resistant starch is supposed to prevent immune 
system recognition of dietary antigens. 
 (from Davis Richardson and Triplett, 2015) 
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3.2  GUT P ERM EABILITY  AN D TYP E 1 DIAB ET ES :   
THE EXPER IM ENTA L EVI DEN C E 
In recent years multiple evidence of a correlation between T1D and gut 
permeability has been produced in both animal models and patients by means 
of functional and histological studies100. 
Concerning this aspect the BB-DP rat has been the most studied animal 
model. The first study from Meddings and collaborators103indicated an 
alteration of stomach and small intestine (SI) permeability, while colonic 
permeability appeared normal. Interestingly this alteration was present before 
the onset of insulitis and diabetes. A more recent study104 demonstrated that 
both BB-DP an BB-DR rats had an increased permeability in comparison with 
the Wistar rat, the common progenitor of the two colonies, and showed an age-
dependent decrease of gut permeability. From the histological examination a 
decrease in the expression of claudin-1 emerged in BB strains, compared with 
Wistar rat104.A study105proved that hydrolyzed formula was able to reduce 
autoimmune diabetes incidence by 50% in BB-DP rat and improve intestinal 
permeability in terms of decreasing lactulose/mannitol ratio, decreasing serum 
zonulin levels and increasing ileal transepithelial resistance. The hydrolyzed 
diet also modified ileal mRNA expression of TJ proteins. Similar result came 
from studies made with gluten-free diets106 
Gut permeability in NOD mouse has been explored in a single study 
conducted by Lee and collaborators107. In this study the authors aimed to assess 
intrinsic barrier function in mice at different ages by measuring serum levels of 
FITC-labeled dextran and the impact on insulitis development of infection by 
strains of an enteric bacterial pathogen (Citrobacter rodentium) either capable 
(wild-type) or incapable (lacking of a specific toxin) of causing intestinal 
epithelial barrier disruption. The study found an increased barrier permeability 
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compared with the non-obese diabetes resistant (NOR) control mice at 12 
weeks, prior to the onset of diabetes,  but not at 4 or 8 weeks. The wild-type 
strain of Citrobacter rodentium caused an increase in intestinal permeability and 
accelerated insulitis promoting proliferation and activation of diabetogenic 
CD8+ T cells. 
Results in humans came from functional and histological studies on 
intestinal biopsies. Except for an early report in 1980s’108,109, the first study on 
gut permeability on patients was performed by Carratù and colleagues110. In 
this study intestinal permeability to cellobiose and mannitol was investigated in 
31 patients affected by T1D. The study showed an unexplained increase in 
intestinal permeability to mannitol compared to controls in presence of a 
normal cellobiose/mannitole ratio. This result was confirmed by another study 
who associated this alteration to the high-risk for celiac disease HLA-DQB 1*02 
allele111. An increase in the lactulose/mannitol excretion ratio was detected by 
Bosiet al.112 in a study on 81 subjects with islet autoimmunity, new onset and 
long onset diabetes. This cross-sectional study indicate that the increased 
intestinal permeability to lactulose precedes the clinical onset of T1D and is 
detected as uniformly altered during the whole course of the disease, 
independently of abnormalities secondary to insulin deficiency. This result was 
confirmed by further studies113,114. An increased circulation of zonulin was 
found in patients with T1D and some of their relatives. Increased zonulin levels 
correlated with increased intestinal permeability in vivo as well as changes in 
claudin-1, claudin-2, and myosin IXB genes expression and increased gut 
permeability114. Genetic studies have found an association between some 
polymorphisms of myosin IXB (MYOB9B), a Rho family GTPases that 
contributes to remodel TJs assembly, and a reduced risk of developing T1D115. 
Morphological studies have not showed any differences at light microscopy 
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between control and T1D patients. Ultrastructural examination highlighted 
several alterations on the apical side of enterocytes, morphological anomalies in 
TJs structure and an enlargement of intercellular spaces113.  
These lines of evidence clearly suggest a role for gut permeability in T1D 
pathogenesis: increased intestinal permeability allows antigens to be drained 
into the PLNs, where they can potentially activate lymphocytes that have access 
to the pancreas. These activated lymphocytes could then mediate β-cell damage 
causing T1D.  
Different potential intervention have been proposed to improve this 
component of the intestinal environment100. Many dietary intervention, 
including hydrolyzed formulae, delayed exposure to gluten, gluten-free foods, 
and omega-3 polyunsaturated fatty acids, have been proposed but none of these 
interventions proved to be clearly beneficial for the development of the 
disease100. Probiotics have been largely studied as well, and they have proved to 
strengthen intestinal TJs and prevent autoimmune diabetes in NOD mice100. 
Fecal transplants represent a radical strategy to restore an healthy microbiota 
and an efficient mucosal barrier116.A promising pharmacological approach may 
be represented by GLP analogues. GLP1 has been widely used in T2D and have 
proved efficacious in some clinical trials in T1D100, probably acting on different 
targets within the intestinal environment. GLP2 is known to induce an 
improvement of intestinal permeability, even if GLP2analogs were not able to 
modify the onset of diabetes in the NOD mouse117. Another potential 
pharmacological approach exploits zonulin inhibitors, a novel class of drugs in 
development for the treatment of CD, that target zonulin receptor preventing 
the zonulin-dependent opening of the TJs. Treatment with a member of this 
family was reported to reduce the cumulative incidence of T1D by 70% in BB-
DP rats118  
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THE INTESTINAL IMMUNE SYSTEM AND ITS ROLE 
IN PANCREATIC AUTOIMMUNITY  
 
 
4.1  THE INT EST INAL  IM MUN E SYST EM:  A G EN ERAL  OV ERVIEW  
The intestinal immune system represents the largest part of the immune 
system and probably the most complex one119.Its role is to cope with the normal 
antigenic burden represented by food and commensal flora without triggering 
chronic inflammation and at the same time to elicit strong immune reactions in 
case of harmful infections, that often origin from the intestines. This necessity to 
protect the integrity of epithelial barrier in normal conditions can explain the 
peculiar tendency of immune mucosal system to induce local and systemic 
immunological tolerance to luminal antigens, a mechanism known as oral 
tolerance119.  
The intestinal immune system is organized in three anatomical distinct sites: 
the organized gut-associated lymphoid tissue (GALT); the mucosal lamina 
propria (LP); and the mucosal surface epithelium. The GALT is constituted by 
isolate lymphoid follicles, PP, defined as an aggregation of at least 5 lymphoid 
follicles, found principally in the ileum, the appendix and MLNs. In this context 
the GALT acts as induction site for the immune response while lymphocytes 
scattered in the mucosal epithelium and LP act as the effector component119. 
Several different cells arising from myeloid and lymphoid lineages with 
peculiar properties interacts at the level of intestinal mucosal environment with 
the active contribution of non-immune cells such as IECs, follicle associated 
epithelium (FAE) and Paneth cells (FIG.8). 
4 
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Figure 8. The immune mucosal system 
Lumen is thoroughly colonized by commensal bacteria. Mucus secreted by goblet cell prevent direct contact of 
bacteria with epithelium, with the exception of follicle associated area, where M-cells directly transport antigens 
from the lumen to the PP where they are processed by DCs. Gut barrier includes the epithelial TJs, sIgA, and 
antimicrobial protein (AMPs) secreted by Paneth cells. In intestine, neutrophils are recruited early to 
inflammatory sites to clear present pathogens. Mast cell and eosinophils can promote defense against 
parasites and induce allergy. Macrophages, DCs, and innate ILCs could sense antigens and then secrete 
cytokines or chemokines to regulate the inflammatory responses. Activated DCs, after sensing luminal antigen 
with their intraluminal dendrites, move to MLNs and PP where they prime lymphocytes. In the presence of pro-
inflammatory cytokines and costimulatory factors, this process induce Th1 and Th17 differentiation. Some 
innate immune regulatory cells such as M2 macrophages induced by interleukin IL-4 and IL-13 could directly 
inhibit effector T cells through IL-10 secretion and promote Treg suppressive function by producing TGF-β. 
CD103+ DCs also regulate intestinal inflammation via facilitatingTreg differentiation in a TGF-β- and retinoic 
acid (RA)-dependent manner. ILC3 serve as an APC promoting Th17 differentiation and could secrete IL -22 
that participates in the repair of impaired epithelium. In response to parasitic infection epithelium produce IL-25 
and IL-33 stimulating ILC2 to produce IL-5 and IL-13 promoting Th2 response. The primarily regulatory cells 
are Tregs that suppress effector T -cell differentiation and proliferation by producing IL-10 and TGF-β or 
expressing CTLA-4 (CD152). The IL-10-producing type 1 regulatory T  (Tr1) cells perform also anti-
inflammatory functions. Moreover, T  helper type 3 (Th3) cells, regulatory Bcells (Bregs), and IELs have the 
capacity of suppressing excessive Th1 and Th17 responses through IL-10 and TGF-β production. These 
immune regulatory cells collectively maintain the intestinal homeostasis by interacting with each other. 
(from Sun et al., 2015) 
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From the lumen the first immunologic defense is represented by secretory IgAs 
and antimicrobial peptides(AMPs)in the inner part of the mucus layer. IgAs 
make up to 75% of the total immunoglobulin produced in the body (intestinal B 
cells resident in LP produces about 3 grams per day of IgAs). IgAs are secreted 
across intestinal epithelia in a polymeric form: two IgAs are bound by a J chain 
and then secreted via transcellular transport mediated by the polymeric Ig 
receptor, which also mediates IgM secretion. The transcytosed IgA then binds 
to luminal bacteria and prevents their translocation across the epithelial barrier. 
IgAs confine bacteria to the lumen through diverse mechanisms, that probably 
include trapping of bacteria in the mucus layer, recruitment of complement 
with subsequent bacterial killing and promotion of phagocytosis of bacteria that 
breach the epithelial barrier120. 
AMPs are natural antibiotics and belong to an evolutionarily ancient defense 
system, present in virtually all multicellular organisms. They are produced by 
IECs and in SI by Paneth cells, a unique population located at the base of crypts 
of Lieberkühn. They can be divided in 4 main groups: enzymatically active 
antimicrobial protein (such as lyzozyme, secretory phospholipase A2, RNases), 
defensins (highly basic protein that bind to negatively charged phospholipids 
building pores in microbial cell membrane), cathelicidins (that intercalate 
themselves in microbial membranes), C type lectins (that promote direct killing 
of Gram-positive bacteria by binding to their peptidoglycan)121 
IECs form a delicate single layer of simple columnar epithelial cells, rapidly 
self-renewing from stem precursors found in intestinal crypts and common to 
other mucosal cells such as goblet, Paneth and enteroendocrine cells. They 
separate the host internal sterile milieu from the external environment but also 
allow the absorption of nutrients, water and ions from the lumen. An immune 
function is now being acknowledged to IECs. They secrete AMPs and transport 
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IgAs, regulating the composition of the microbiota. Conversely they can sense 
microbiota by expressing TLRs. They can also express MHC class I & II and 
non-polymorphic MHC-related molecules such as CD1, thus presenting 
antigens to surrounding lymphocytes. They also act on the mucosal layer 
secreting different chemokines and cytokines. In this way IECs act as central 
organizers of the immune response, integrating luminal stimuli and prompting 
DCs and IELs towards a tolerogenic or pro-inflammatory behavior122,123,124. A 
specialized subset of epithelial cells, overlying the organized mucosal lymphoid 
tissue, forms the Follicle associated Epithelium (FAE), characterized by the 
presence of M cells (micro-fold cells). FAE is designed to allow direct contact of 
luminal content to the apical surface and therefore lacks the normal defensive 
features of intestinal epithelia such as mucus or antimicrobial peptides. M cells 
are able to deliver luminal components, even whole bacteria, by transepithelial 
endocytosis to their basolateral domain that consists of an intraepithelial pocket 
containing DCs, naïve T cells and B cells. FAE is thus crucial in the fine balance 
of host-microbe symbiosis, but is also a potential open gate to invasive viral and 
bacterial pathogens. Sampling of luminal antigens has been proved to happen 
also by two other routes: antigens bound by IgGs can be directly transported 
into the intestinal LP through the neonatal Fc receptor for IgGs and DCs can 
project dendrites between IECs into the lumen without disrupting gut barrier 
integrity124. 
A particular population of lymphocytes, the so-called intra-epithelial 
lymphocytes (IELs), is scattered in the context of the gut columnar epithelium. 
Under normal conditions there is one IEL every 3-10 IECs in SI and one IEL 
every 40 IECs in LI, making IELs one of the most abundant lymphocyte 
populations in the body. IELs are under other aspects a unique lymphocyte 
population, distinct from peripheral lymphocytes but also intrinsically 
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heterogeneous to adapt to the different contexts of the GI tract: face food 
antigens in SI and control resident flora in LI. IELs are generally T cells (B cells 
are only present in the context of PP) and a high prevalence of them expresses 
the γδ T cell receptor (TCR), and many inhibitory and activating NK receptors 
such as CD16124. IELs are antigen-experienced cells and most of them express a 
cytotoxic phenotype. After stimulation they usually produce low levels of 
cytokines, to preserve gut barrier integrity. Their gut homing is guaranteed by 
the expression of the αEβ7 and α4β7 integrins that binds to epithelial E-cadherin. 
In normal conditionsCD4+ IELs are uncommon, while many IEL appear CD4-
CD8- or, as a hallmark of activated cell, especially in SI, they expose on their 
surface CD8αα homodimers. This co-receptor binds to the non-classical MHC 
class I molecule thymus leukemia antigen (TLA) expressed by IECs. Depending 
on which pathway leads to an antigen-experienced phenotype, IELs are divided 
in natural IELs (nIELs), which undergo a self-antigen induced differentiation 
process in the thymus and induced (iIELs) that acquire their activated 
phenotype peripherally (FIG.9)125. 
nIELs can be either TCRαβ+ or TCRγδ+, after thymic selection they directly 
home, as double negative CD4- CD8-,to the gut where they can start to express 
the CD8ααupon stimulation with IL15 produced by IECs. TCRγδ+ nIELs are 
essential in maintaining epithelial homeostasis, producing keratine growth 
factor and controlling the production of IFN-γ by activated IELs. However 
TCRγδ+ nIEL can themselves produce pro-inflammatory cytokines like IL-17 in 
case of infection126. This is possible thanks to the co-occurence on their surface 
of both activating and regulator molecules126.TCRαβ+ CD8αα+nIELsare probably 
the most peculiar IELs subset: they exhibit an activated phenotype but they do 
not easily proliferate and seem to promote immune quiescence rather than 
immune responses. This feature could be linked to the expression of the CD8αα 
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receptor, that can bind TCR activating signaling molecules such as the 
lymphocyte-specific protein tyrosine kinase (Lck) and linker for activation of T 
cells (LAT) but is unable to move into the lipid raft adjacent to TCR, resulting in 
a sequestration of these stimulatory factors, raising the threshold for cell 
activation. Like their TCRγδ+ counterparts, however, TCRαβ+ CD8αα+ 
nIELshave been proved to have an effector role in case of infection. Their 
cytotoxicity and self-reactivity probably allows them to respond also to 
transformed epithelial cells124,127.  
 
 
 
 
  
Figure 9. IEL differentiation 
Immature thymocytes, showing a CD4+CD8αβ+ CD8αα+ triple positive phenotype, can undergo agonist 
(alternative) selection and differentiate in double negative CD4 - CD8αβ- cells with TCRαβ and TCRγδ 
expressing intestinal homing receptors. When they reach the intestinal epithelium they become natural 
IELs that can express or not CD8αα. Double positive thymocytes undergo conventional positive 
selection becoming classic TCRαβ+CD4+ or TCRαβ+ CD8αβ+ cells. In MLNs or PP they are primed by 
their antigens and enter the induced IEL compartment. The gut environment can induce CD8αα 
expression also on these cells.  
(from Cheroutre et al., 2011) 
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iIELs derive from CD4+ or CD8αβ+ MHC class I or class II restricted T cells 
developed in the thymus under the conventional selection pathway and moved 
to MLNs where they responded to their cognate environmental antigens. They 
subsequently home to the gut where they can start expressing the 
CD8ααhomodimer. CD8+iIELs have usually cytotoxic effector memory 
phenotype, they are mostly TCRαβ, their repertoire appear more restricted than 
that of peripheral cells probably because repeated antigenic stimulation lead to 
survival of selected clones.CD4+iIELs can encompass all CD4+ helper subsets 
(Th1, Th2, Th17, Foxp3+Tregs) or be CD4+CD8αα+cytotoxic T lymphocytes, a 
newly recognized population constituted by CD4+ cells that remainMHC class II 
restricted but post-thymically lose the expression of the CD4 specific 
transcription factor ThPOK, leading to a derepression of their cytolytic gene-
expression program. They are probably involved in the control of viral 
infections but also showed a protective anti-inflammatory functions128.In the 
gut, however, an extreme plasticity between the different kind of CD4 subtypes 
have been described129.iIELs share with nIELs the presence of NK receptors. In 
this way both nIELs and iIELs appear to share the ability to sense stressed and 
transformed IECs while being able to start a protective response in absence of 
pre-exsisting antigen induced immunity or after repeated antigen challenges 
respectively. The complexity and sophistication of IELs respond to the necessity 
common to all GI mucosal immune system to avoid excessive immune response 
to innocuous food antigens and bacterial commensals while providing effective 
protection against potential pathogens (FIG. 10). IELs dysregulation either in 
CD4+ or CD8+ subsets are been involved in the development of intestinal disease 
such as IBDs and CD127. 
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Figure 10. IEL differentiation and function in intestinal homeostasis  
IELs play a crucial role in protection of the intestinal mucosal barrier. During infections rapid activation 
of the CD8αβ+ IEL contribute to the prevention of pathogen spreading by killing infected IECs. Activate 
DCs promote the differentiation of Th17 cells via a combination of IL-6 and TGF-β. In homeostasis the 
CD8αα receptor is expressed and gut-derived CD103+ DC and LP macrophages favor the conversion 
of Foxp3+iT regs in a RA, TGF- β, and IL-10 mediated fashion. Finally, in the LP is also naturally 
occurring nTreg are found. 
(from van Wijk and Cheroutre, 2009) 
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In the LP, the thin layer of loose connective tissue which lies beneath the 
epithelium, the predominant T cell population is constituted by CD4+ T 
lymphocytes, while CD8+T lymphocytes were predominant in the epithelium. 
LP lymphocytes (LPLs) integrate signals from multiple cell lineages such as 
IECs, stromal cells, DCs, macrophages, basophils, eosinophils, mast cells and 
from the matrix via integrin receptors124. LPLs express the homing receptors 
CCR9 and α4β that they express after exposition to RA produced by DCs 
moving from the gut to MLNs. LPL show an activated phenotype, several 
subsets are represented and an extreme plasticity between the different kind of 
CD4+ subtypes have been described. Under normal condition Th1 (mainly 
producer of IFN-γ expressing the transcription factor Tbet, responding to 
intracellular pathogens and assisting with viral infection) and Th17 (producer 
of IL-17 and IL-22 expressing the transcription factor RORγ, protect mucosal 
integrity from infectious agents by different mechanisms) appear to be the 
dominant effector phenotype present in the gut in absence of helminthes, that 
instead induce the differentiation of Th2 lymphocytes (producer of IL-4 and IL-
2 expressing the GATA3 transcription factor). Also the newly characterized 
subset Th22 (producing IL-22 a cytokine with epithelial reparative and 
regenerative properties) and Th9130 (involved in allergic reactions, 
autoimmunity but also response to tumors and nematodes) are represented. T 
Follicular helper (Tfh) cell appear essential in the maintenance of germinal 
center and PP, where they participate in the induction of IgA class isotype 
switching131.  
The potential pro-inflammatory action of conventional T cells is balanced by 
the presence of Treg subtypes. These are an heterogeneous populations of cell 
able to inhibit APCs and effector cells by direct contact mediated by CTLA-4 
(CD152), or release anti-inflammatory cytokines such as IL-10 and TGF-β132. 
A 
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They have been divided in nTregs and induced Treg iTregs, similarly to IELs 
described above, even if the denominations Thymus-derived Tregs (tTregs) and 
Peripherally derived Tregs (pTregs) have been proposed by a recent consensus to 
describe these populations133.nTregs origin from the thymus where they are 
primed with self-antigens, then they migrate as antigen experienced cell 
expressing a CD4+CD25+Foxp3+ phenotype to maintain peripheral self-tolerance 
(this mechanism is also called central tolerance). They typically express the 
transcription factor Helios. iTregs are derived from naïve T cells that start 
expressing Foxp3 transcription factor in periphery under the influence of the 
cytokine milieu present or after chronic low dose antigen stimulation (while 
high dose chronic stimulation tend to induce cell deletion or a state of 
hyporesponsiveness called anergy).TGF-β, IL-10, IL-35 have been characterized 
in vivo and in vitro as the key factors in inducing specific Treg subpopulations 
(respectively Th3134, Tr1135, and iTR35136 cells). A new field of study is constituted 
by the study of the specific feature of Tregs resident in different tissues, the so-
called unconventional Tregs137. Gut Tregs in this sense appear as an 
heterogeneous population of nTregs and iTregs, can co-express GATA3 along 
with Foxp3 and IL33 seem to play an important role in their differentiation137. 
Specific abundant bacteria such as Bacterioides fragilis and Faecalibacterium 
prausnitzii can induce specific Treg subsets. In humans LP a 
CD4+CD8αα+population with regulatory properties such as IL-10 secretion has 
been recently found and involved in IBD pathogenesis. This population is 
probably an equivalent of mouse conventional Foxp3+ LPLs and appear to 
respond specifically to Faecalibacterium prausnitzii antigens138.Lymphocytes with 
regulatory properties have been described also among CD8+ cells139and B cells 
(Bregs)140. 
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Innate lymphoid cells (ILCs) are a growing family of immune cells that 
mirror the phenotypes and functions of T cells and have an important role in 
gut homeostasis. They comprehend the well-known NK cells that can be 
considered the innate counterparts of cytotoxic CD8+ T cells, and ILC1s, ILC2s, 
and ILC3s that represent the innate counterparts of CD4+Th1, Th2 and Th17 
cells respectively. ILCs are evolutionary precursors to T cells that are 
fundamental for their ability to react immediately to signals from infected or 
injured tissues, producing cytokines that can direct the developing of adaptive 
immune response, especially influencing the antigen presentation by DCs141. 
DCs are one of the most important components of immune system since they 
are the most effective APCs to initiate primary immune responses and link 
innate and adaptive immunity140. DCs take up antigens, process them and 
present antigens to T cells. Besides they directly influence the type of immune 
response which is going to develop: inflammatory in case of pathogens and 
tollerogenic if commensal microflora is presented. According to the expression 
of the surface marker CD103, intestinal DCs can be divided into two 
predominant subsets: CD11chigh CD103+ and CD11chighCX3CR1+CD103- DCs. 
CD103+ DCs, found deeper in LP, promote Treg induction secreting TGF-β and 
RA and expressing the indoleamine 2,3 dioxygenase (IDO) enzyme, that reduce 
local tryptophan concentration, easing Foxp3 upregulation by TGF-β and RA. 
CX3CR1+ DCs instead are located near the IECs and produce transepithelial 
dendrites, produce pro-inflammatory cytokines like IL-6 that promote Th1/Th17 
differentiation124,142. In the context of PP and MLNs DCs have a pivotal role in 
inducing IgA switching in B cells124,142.  
Macrophages represent a massive population in LP and plays an important 
role in gut immune system homeostasis Macrophages display plasticity in their 
activation profile under different cytokine conditions. M1 macrophages 
TYPE 1  D IA BETES  A ND  THE G UT 
 
55 
 
induced by IFN-γ and microbial products are characterized by microbicidal 
activity and pro-inflammatory properties. However, M2 macrophages, induced 
by IL-4 or IL-13, display an anti-inflammatory phenotype. Intestinal 
macrophages, in presence of an intact epithelium, are characterized by a TGF-β-
induced state of inflammatory anergy and inability to present antigens due to 
NF-κB inactivation accompanied by a avid phagocytic and bacteridal activity 
that allows them to quickly cope with enteric microbes and apoptotic cells 
before they can elicit a structured inflammatory response124,140. 
Granulocytes are also largely represented in gut. Neutrophils can be earlier 
recruited to inflammatory sites to clear the pathogens present. Basophils are 
well known effector cells in inflamed tissues, where they secrete histamine after 
activation via IgEs bound on their surface. New roles have been recently 
recognized to this population as the ability to express TLRs, secretion of ILs 
after stimulation by parasites, activity as APCs for the induction Th2 immunity. 
Eosinophils are able to secrete a wide range of soluble mediators like cytokines 
and chemokines, eicosanoids, anti-helmintic proteases, tissue repair factors. In 
the gut, they present an activation phenotype and degranulate after liberation, 
by mast cells or Th2 lymphocytes, of IL-3 or IL-5. They can also act as APCs and 
interface with the enteric nervous system promoting nerve remodeling and 
changing in neurotransmitter activity. Mast cells are resident within mucosal 
tissue, unlike eosinophils and basophils that are recruited by blood circulation. 
The principal stimulus for their stimulation is represented by cross-linking of 
cell-surface-bound IgEs by allergens but they are sensible also to IL-4 and stem 
cells factor. Their activity is fundamentally mediated by their secretory 
products that encompass a large range of molecules like histamine, tissue 
proteases, ILs, eicosanoids, acting on multiple aspects of intestinal homeostasis, 
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epithelial secretion and permeability, blood flow, peristalsis, wound healing 
and fibrosis124. 
4.2  THE COMP L EX BALAN C E B ETW EEN M ICROB IOT A AN D  
THE MUC OSAL IM MUN E S YST EM  
A complex bidirectional interaction exists between the microbiota and the 
mucosal immune system. This is the product of a long co-evolution between 
vertebrates and its symbionts. In particular the adaptive immune mechanisms 
exclusive to this phylum, such as IgAs secretion, promoted colonization of the 
alimentary tracts by exerting selective pressures that favored resident microbes 
that were relatively innocuous, but metabolically useful for the host143. The 
bacterial communities appear, moreover, essential for the development and 
function of the immune system that, on the other hand, shapes the composition 
of microbial flora. The breakdown of this balance, because of changing of 
intestinal flora or abnormalities of immune system is now being recognized as 
important pathogenic mechanism in intestinal and extraintestinal disease144.This 
recognition of an immunoregulatory role for the microbiota could be 
considered as an evolution of the ‚hygiene hypothesis‛ that tried to explain 
why autoimmune and allergic disease incidences positively correlate with the 
level of sanitization of a population. Metagenomic studies are now showing 
how modern life style, exposure to antibiotics, the absence of chronic infection 
with the so called ‚old friends‛ (helmynths, protozoa, mycobacteria) changed 
our microbial community and probably its ability to promote the a correct 
balance between effector and regulatory population of human immune 
system145. 
GF animals, actually, show impaired development of the GALT especially PP 
and isolated lymphoid follicles. As far as effector T cells are concerned a switch 
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towards Th2 response have been described. The development of Th17 cells have 
been proved to be linked with mucosal colonization. In mice SFB are one of the 
principal triggers of Th17 differentiation, but also human flora is able to induce 
the development of this subset in the murine model. Different mechanisms 
have been proposed to explain this influence of microbiota on Th17 
differentiation: TLR stimulation of bacteria on resident phagocytes induce them 
to produce IL-1β, that consequently induce Th17 differentiation in the intestine; 
also luminal ATP produced by some resident species has been proposed to 
induce Th17 differentiation promoting DC activation; eventually SFB 
colonization lead to production of serum amyloid A by IECs that could induce 
Th17 pathway144. Also iTregs need the microbiota to fully develop, especially in 
the colon. In particular Clostridia species are able to induce a robust 
accumulation of iTregs in mice. This process appeared impaired in MyD88 
deficient mice suggesting a role for innate immunity receptor in this process.  
SCFAs produced by commensals are probably a key element in development of 
the colonic Tregs. In particular butyrate was shown to be able to increase 
acetylation of the Foxp3 locus, epigenetically promoting its expression. SCFAs 
can induce IECs to produce TGF-β that with RA is a key factor for induction of 
Tregs in the gut. Microbiota, moreover, induce GPR15 a gut homing molecule 
for Tregs. Not only Clostridia but also colonization of mouse intestine with the 
human commensal Bacteroides fragilis resulted in a rise of Tregs and IL-10 
production in mice, a process mediated by TLR2 signaling induced by 
polysaccharide A144,146. IgA isotope switching in intestinal B cells is impaired in 
GF mice that tend to have a higher number of IgE B cells compared with 
conventionally raised mice. This process appears mediated by the activation of 
TLR-MyD88 pathway in LP DCs and follicular DCs that induce the secretion of  
TGF-β, CXCL13, B-cell activating factor (BAFF), and A Proliferation Inducing 
Ligand (APRIL) that promote IgA epitope switching147. Also differentiation of 
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group 3 ILCs according to some studies appears dependent on microbiota 
stimulation and the microbiota appears to be an important modulator of IL-22 
production by this population. LP macrophages are dependent on microbiota to 
process and secrete IL-1β from pro-IL-1β, in particular flagellin from invasive 
species such as Salmonella is a potent inducer of IL-1 production. Also the anti- 
inflammatory function of intestinal macrophages, such as spontaneous 
production of IL-10, is controlled by the microbiota, in a MyD88-independent 
manner as showed in MyD88 knockout models144.  
The immune system deeply affects the microbioma and its composition. First 
of all it limits the penetration of luminal bacteria into the GI mucosa by 
different means such as luminal IgAs, the antibacterial lectin RegIIIγ produced 
by IECs stimulated by IL-22 from group 3 ILCs, and the ability of neutrophils to 
form intraluminal cast after pathogen invasion144,146. Mice with immune 
deficiency showed alteration of microbiota. In particular alteration of IgA were 
showed not only to change the amount of species present but also expression of 
bacteric genes, leading potentially harmless bacteria to become harmful. 
Alterations of group 3 ILCs deficient in IL-22 secretion can lead to abnormal 
expansion of SFB that in turn can induce a upregulation of Th17 cells, resulting 
in a worsening of extra-intestinal autoimmune disease such as arthritis and 
experimental autoimmune encephalomyelitis (EAE), the experimental model of 
MS143. 
Intrinsic alterations of gut immune system, and of its interaction with 
resident flora could play an important role also in T1D. In the next section I will 
try to summarize the evidence supporting this idea.  
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4.3  GUT IMMUN E SYST EM AN D PANCR EATIC AUT OIMMUN ITY :   
LOOKING FOR T HE M ISS ING  LIN K  
In experimental studies, several indications of the involvement of gut 
immune system in the development of autoimmunity have been described in 
murine models and patients.  
A first line of evidence came from studies that showed, both in men and 
murine models, that islet infiltrating Tcells show mucosal homing properties 
such as expression of gut-associated homing receptor β7-integrinimplying a 
link between the mucosal immune system and the pancreas. It has been also 
showed that PLNs, especially in a context of altered mucosal barrier, process 
not only pancreatic antigens but also microbial and dietary ones. Moreover, in 
NOD mouse, diabetogenic T cells are present in the gut-associated immune 
system, so that mesenteric lymphocytes from a young NOD mouse can transfer 
autoimmune diabetes to the recipients43,51,148. 
A second group of observations came from histological studies of murine 
and animal intestinal samples. In BB-DP rats a CD-like enteropathy 
characterized by crypt hypertrophy and hyperplasia, increase in the proportion 
of IELs, a decrease in brush border enzyme activity, and increased infiltration of 
the mucosa by CD4+ T cells was described to precede the onset of the disease, 
even if a causal link between the two conditions could not be established42.NOD 
mice were shown to have less IELs than NOR or BALB/c strains in histological 
studies. Also in BB-DP rats it has been reported that a deficiency in IELs occurs 
prior to the onset of diabetes149 Neonatal thymectomy markedly impaired the 
IELs deficiency and accelerated autoimmune diabetes in NOD mice. Transfer of 
CD8αα+TCRγδ+IELs in NOD mice which underwent to neonatal thymectomy 
resulted in diabetes prevention. The induction of Tregs by oral insulin appeared 
dependent on TCRγδ+IELs150. In contrast to these observations Markle et al.151 
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showed that IL-17-producingTCRγδ+ T cells mediate the pathogenesis of T1D in 
the NOD mouse model and suggested that IL-17-secreting TCRγδ+ T cells play 
an effector role rather than a protective role..As far as human studies are 
concerned pioneering studies148,152 explored the immunologic characteristics of 
epithelium and LP in dejunal biopsies from T1D subjects finding enhanced 
immune activation in terms of increased expression of MHC class II antigens 
and ICAM-1,IL-1α– and IL-4–positive cell detected by immunohistochemistry. 
Another study from Auricchio et al.153 found in SI biopsies from 17 children 
with T1Dan increased density of intraepithelial CD3+ and TCRγδ+ cells and 
CD25+ mononuclear cells in LP. These findings of intestinal immune activation 
were not restricted to individuals with the HLA DQ2 allele typical of patients 
with CD, so the altered intestinal immunity in T1D appears to represent a 
separate entity from CD. Even if the patients had not serological markers of CD, 
biopsies cultured with peptic-tryptic gliadin showed deranged mucosal 
immune response to gliadin characterized by an epithelial infiltration by CD3+ 
cells, a significant increase in LP CD25+ and CD80+ cells and enhanced 
expression of LP CD54 and crypt HLA-DR. No such phenomena were observed 
in control subjects, even those with CD–associated HLA haplotypes. Matrix 
metaloproteinases (MMP) are a group of enzymes produced by several 
different cell types and released in response to inflammation to remodel he 
extracellular matrix but also able cause tissue damage. In a study in a cohort of 
children positive for transglutaminase antibodies, the subgroup of children 
with T1D showed higher expression of MMP sand increased proportion of 
apoptotic mucosal cells than children without T1D154. Alteration in effector T-
cell subpopulations have also been reported: in NOD mice colonic LP T cells 
express higher levels of both IL-17 and IFN-γ and MLNs have increased Th17 
and Th1 effector T cells155. In children with T1D an upregulaton of Th17 cells in 
peripheral blood have been shown 149. Biopsy studies were conducted also to try 
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to understand the role of Tregs in T1D patients156: a low numbers of Foxp3+ cells 
or Foxp3 transcripts were found and an increased transcription of the pro-
inflammatory cytokine IL-18. The decrease of intestinal Foxp3 activation in T1D 
provides a rationale for further investigation. Can impaired regulatory 
mechanisms explain the subclinical intestinal immune activation and altered 
responses to dietary antigens? What is the link between intestinal inflammation 
and the development of pancreatic autoimmunity? 
Taken collectively these findings show that an altered activation of the immune 
system in the intestinal mucosa is present and provide a new focus on the 
potential role of intestinal immunity in the pathogenesis of T1D51 
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This thesis is the result of a 3-month internship which I served at Professor 
Chantal Mathieu’s Clinical and Experimental Endocrinology lab at the 
Katholieke Universiteit Leuven (KU LEUVEN) in Belgium. This period was for 
me a fundamental and enriching opportunity to be introduced to the 
experimental research in the field of mucosal immunology. 
The aim of this thesis is to characterize different aspects of the gut 
environment in the NOD mouse at different ages and stages of disease to 
highlight possible correlation between intestinal alterations and the 
development of pancreatic autoimmunity. In particular, the features of 
lymphocyte populations resident in the intestinal epithelium and LP and gut 
permeability will be described. These variables will be evaluated in the context 
of a wider characterization of the immune system of the mice that will involve 
evaluation of regulatory T lymphocyte population in spleen, PP, MLNs, PLNs, 
the presence of IAAs, insulitis scoring of pancreas samples. 
Eventually these results will be correlated with the metagenomic 
characterization of fecal samples, which at the time of this thesis defense is still 
ongoing, and should be considered preliminary to planned interventional 
studies that will evaluate the effects on the intestinal ecosystem of different 
experimental procedures such as vitamin D supplementation or induction of 
oral tolerance toward insulin antigens.  
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1 Animals 
NOD mice were housed and inbred in animal facility of the KU LEUVEN. 
Housing of NOD mice occurred under semi-SPF conditions, and animals were 
fed sterile food and water ad libitum. NOD mice were screened for the onset of 
diabetes by evaluating glucose levels in urine (Diastix; Bayer Diagnostics, 
Tarrytown, NY) and venous blood (AccuChek, Roche). Mice were diagnosed as 
diabetic when having glycosuria and blood glucose measurements exceeding 
200 mg/dl for two consecutive days. Four groups of 5 female mice were used for 
the studies: 3 week-old (3W), 8 week-old (3W), new-onset diabetic NOD mice 
(progressors) and long-term non-progressor NOD mice. Mice were considered 
recent onset diabetic when hyperglycemia was present for less than a week. 
Mean age of progressors mice was 15 weeks, while non-progressor mice was 27 
weeks when sacrificed. 
2 FITC-Dextran essay 
After a fast of 4 hours, 100 μl FITC-labeled dextran (FD4; Sigma-Aldrich)at 
the concentration of 40 mg/ml was introduced to mice by oral gavage. After 4 
hours animals have been sacrificed and serum was collected by cardiac 
punction. Pancreas were harvested for insulitis scoring The sera is then diluted 
with PBS in 1:1 proportion and immediately read on a Victor3fluorometer  
(excitation 485/ emission 535 nm, Perkin Elmer, Waltham, MA, USA). 
3 Insulin auto-antibodies (IAA) determination 
Sera from sacrificed animals were collected by cardiac puncture and sent for 
Radio Immunologic Assay analysis for the presence of IAAs to Prof. Atkinson 
laboratory at the University of Florida, Gainesville, FL,USA).  
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4 Histology of pancreas and insulitis grading 
As already described157, six micron sections from formalin-fixed paraffin 
embedded pancreata of each animal were cut and collected 100-μm apart, then 
stained with hematoxylin eosin. Islets were observed under light microscopy at 
20× or 40×, enumerated and graded. At least 25 islets per pancreatic sample 
were scored for islet infiltration as follows: 0, no infiltration; 1, peri-insulitis; 2, 
islets with lymphocyte infiltration in less than 50% of the area, 3, islets with 
lymphocyte infiltration in more than 50% of the area or completely destroyed.  
5  Organ harvesting  
SI (duodenum, jejunum and ileum) and LI (caecum and colon) were 
collected. The PP, found along the ileum and on the jejunum, were removed at a 
later stage and kept separately for analysis. The MLNs, PLNs and spleen were 
also removed. All organs after removal were immediately placed in ice-cold 
DMEM (Gibco, Invitrogen, Carlsbad, CA) supplemented with 5% fetal calf 
serum (FCS, Thermo Fisher Scientific). 
6 IELs and LPLs isolation 
The IELs and LPLs were isolated from the four groups of mice mentioned 
above. The intestines, after harvest, were polished from additional fat and PP 
were excised. Then they were longitudinally cut and cleaned from fecal matters, 
finally cut into pieces of approximately 0.5 cm. The pieces were put in 20 ml 
DMEM-5% FCS and placed at37°C horizontally in a shaking incubator at 250 
rpm for 20 min. The tissue suspension was poured through a metal strainer, 
collecting the supernatant in a new tube. The remaining intestines were then 
put from the metal strainer in 20 ml fresh DMEM-5% FCS, shaken again, and 
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the supernatant was collected in the same tube. The supernatant was then 
centrifugated at 1500 rpm for 5 min. The intestines were collected from the 
metal strainer and kept for LPL isolation. The pelleted cells were re-suspended 
in 40% Percoll(GE Healthcare, Piscataway, NJ) and layered over 70% Percoll. 
This gradient was centrifuged at 2000 rpm for 25 min without brake at room 
temperature. The interphase, containing the IELs, was collected and transferred 
to a new tube. The cells were washed twice with DMEM-5% FCS and re-
suspended in staining buffer 
To get rid of the remaining IELs that would be isolated during LPL isolation, 
the remaining intestines were washed twice before proceeding. The first wash 
step was in 20 ml DMEM-5% with 20 μl 0.5 M ethylene diamine tetra acetic acid 
(EDTA) (Sigma)and the second wash step was in fresh DMEM-5%. For both 
wash steps the intestines were placed in a shaking incubator at 240 rpm for 15 
min at 37°C.To isolate the LPLs, the remaining intestinal tissue was minced and 
transferred to a new tube. The minced intestines were put in DMEM-2% FCS 
containing 0.5 mg/ml of collagenase (Sigma) and shaken at 240 rpm for 20 min 
at 37°C. The tissue suspension was poured through a metal strainer, collecting 
the supernatant in a new tube. The LPLs were isolated from the pelleted cells 
using a 40/70% Percoll gradient as described above. 
7 Single cell lymphocyte isolation from lymphoid organs  
MLNs, PLNs; PPs were mashed through a 70 μm with DMEM-5% FCS. 
Spleen samples were treated with a red blood cell lysing buffer (Sigma) for 5 
minutes at room temperature then diluted, to stop the reaction, with cold 
DMEM-5% FCS. Samples were centrifuged and washed once in DMEM-5%. The 
obtained cells were put in FACS Buffer.  
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8 Antibodies used for staining  
The following fluorochrome-conjugated antibodies were used for IEL/LPL: 
eFluor450 anti-CD4(GK1.5),Phycoerythrin (PE)anti-CD8α (53-67), peridinin 
chlorophyll protein-cyanine 5.5 (PerCp-Cy5.5) anti-CD8β, fluorescein 
isothiocyanate (FITC) anti-TCRγδ (GL3), allophycocyanin (APC) anti-TRCβ. 
For lymphoid organs lymphocytes the antibodies used were the following: 
PerCPCy5.5 anti-CD3, PE-Cy7 anti-CD25, APC-H7anti-CD4, efluor450anti-CD8, 
and the intracellular staining PE anti-CTLA-4 and APC anti-FoxP3 
Antibody to mouse CD16-CD32 (93, eBioscience)was used for b locking Fc 
receptors. LIVE/DEAD Fixable Yellow Dead Cell Stain Kit was used according 
to the manufacturer’s specifications (Invitrogen) to stain dead cells.  
9 Staining  
Cells were washed 2 times with FACS buffer prior to staining. All cells for 
IELs/LPLs and a maximum 1 × 106cells for lymphoid organs lymphocytes were 
pelleted in a 96 V-well plate. The cells were incubated with surface antibodies 
in the dark for 15 min at 4 °C. Cells from lymphoid organs were also fixated in 
Fixation/Permeabilization solution (Foxp3/Transcription Factor Staining Buffer 
Set, eBioscience) for 1 hour at 4°C. Antibodies against intracellular epitopes 
were then diluted in Permeabilization buffer (Foxp3/Transcription Factor 
Staining Buffer Set, eBioscience) and incubated with cells in the dark for 40 min 
at 4°C. All the cells were then washed, re-suspended in FACS buffer and 
filtered for acquisition. 
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10 Flow cytometry  
Acquisition of IEL/LPL data was done on Canto II (BD), while lymphoid 
organ samples were run on Gallios (Beckman Coulter) FACS machine and were 
analyzed with FlowJo_V10 software (TreeStar, Ashland, OR).The gating 
strategies are presented in FIG 11 
11 Statistical analysis 
Samples were analyzed with GraphPad Prism 6 software (La Jolla, CA, USA). 
The comparison between NOD mice populations were made using the non-
parametric Mann–Whitney t test. Data are presented as mean ± Standard Error 
of the Mean (SEM). Significance was defined as ns not significant; * p < 0.05; ** p 
< 0.01; *** p < 0.0011  
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Figure 11. IEL/LPL and Treg gating strategies   
A) IEL and LPL gating strategy. Doublets were excluded by the analysis by forward-scatter area 
(FSC-A) versus forward-scatter width (FSC-W) and by sideward scatter area (SSC-A) versus 
sideward-scatter width (SSC-W). Viability was assessed using LIVE/DEAD staining for dead cells; 
live cells showed no signal in this channel. Live lymphocytes were gated into TCRγδ+TCRβ- and 
TCRγδ-TCRβ+ IELs. The latter encompass 3 subtypes: TCRγδ-TCRβ+CD4-CD8β-, TCRγδ-
TCRβ+CD4-CD8β+ and TCRγδ-TCRβ+CD4+CD8β-. CD8αα expression was analyzed in 3 
populations as described above: TCRγδ+TCRβ-CD8αα+,TCRγδ-TCRβ+CD4-CD8β-CD8αα+ and 
TCRγδ-TCRβ+CD4+CD8β-CD8αα+.  
 
B) Treg gating strategy. Doublets were excluded by the analysis by forward-scatter area (FSC-A) 
versus forward-scatter width (FSC-W) and by sideward scatter area (SSC-A) versus sideward-
scatter width (SSC-W). Viability was assessed using LIVE/DEAD staining for dead cells, presence 
of lymphocytes with the expression of the CD3 receptor. CD3 positive cells were then gated in 
CD4+ and CD8+ lymphocytes. CD4+ population was analyzed for the presence of FoxP3 and 
CD25, markers of Tregs. 
 
A. 
. 
B. 
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1 LONGITU DINAL C HARA CT ERIZAT ION O F INSUL ITIS ,  IA A AN D GUT  
PERM EA BIL ITY IN NO D M IC E 
All juvenile NOD mice in our colony developed insulitis starting at about 3 
weeks of age, regardless of their sex (data not shown), but there was 
considerable variation in their progression to diabetes (FIG. 12). Overt diabetes 
developed in 60-80% of female NOD mice and only 20-40% of male NOD mice, 
any time between 12-25 weeks of age (with a mean onset at 15 weeks of age in 
the current study)(data not shown). 
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Figure 12. Insulitis development across different ages in NOD mice 
Pancreatic sections were stained with H&E and insulitis was scored as indicated in materials & 
methods. Histogram depicting the percentage of normal islets (no insulitis, white bar), peri-insulitis 
(light gray bar), insulitis involving <50% of the islet in cross section (mild insulitis, dark gray bar), or 
insulitis involving >50% of the islet (heavy insulitis or complete β-cell destruction). Between 100 and 
305 islets obtained from 19 animals (n = 4-6 per group; 3W, 8W, progressor and non-progressor NOD 
mice) were scored. The frequency of stage 0 insulitis was significantly lower in the 3W NOD mice than 
in progressor mice but also compared to non-progressor mice, and, conversely, heavy insulitis was 
significantly higher in progressors and non-progressors compared to 3W- and 8W-old mice. 
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This heterogeneity in disease penetrance may compromise the accuracy of 
mechanistic studies as we have currently no information on which individual 
mouse will progress to overt disease or not. Here, we studied both IAA and 
intestinal barrier (dys)function to find correlations with disease onset. 
During the study, the percentage of animals with IAA positivity was 
comparable between the different age groups (100, 72, 82% in 3W, 8W, and 
progressor NOD mice, respectively), although the progressors had a higher 
percentage of mice with IAA positivity compared to non-progressors (82 versus 
60%). Moreover, the index of IAA progressively increased with age and reached 
the highest levels in the diabetic progressors (FIG. 13). From these data, we 
suggest that the ontogeny of IAA cannot predict the clinical onset of disease in 
NOD mice. However, most progressors did develop higher levels of IAA than 
non-progressors. 
 
 
 
Figure 13.The natural history of IAA in NOD mice 
Analysis of animals from 3 weeks of age (3W; n = 5), 8 weeks of age (8W; n = 25), disease onset 
(progressor; n = 17) or remaining normoglycemic until 27 weeks of age (non-progressor; n = 5).The 
dashed line represents the definition for positive IAA responses (>9.7). The index of IAA progressively 
increased with age and reached the highest levels in the diabetic progressors. *p<0.05; **p<0.01 by 
non-parametric Mann–Whitney t test. 
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Besides serum IAA, we also studied the gut permeability in NOD mice at 
different ages by measuring serum levels of FITC-labelled dextran. Recent 
evidence suggests a link between intestinal barrier dysfunction and an 
increased risk of T1D in mice and men100. Here, we could not demonstrate that 
pre-diabetic (3W and 8W) NOD mice display increased intestinal permeability  
although all mice developed some degree of islet infiltration. From our data it 
also appears that disease progressors have the highest variability in serum 
FITC-dextran concentrations among the different experimental groups (FIG. 14).  
 
 
 
 
  
Figure 14. Gut permeability in NOD mice at different disease stages 
Serum levels of 4.4-kDa FITC-dextran 4 hours after administration of the marker by gavage in NOD 
mice of different ages and disease stages, n = 5-9 for each data point.  
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2 IMMUN OLOG IC C HARACT ER IZATION STU DY  
2.1 Characterization of IEL in NOD mice at different disease stages 
A large number of differentiated T cells are present within the intestinal 
epithelial surfaces, contributing substantially to the immense size of the gut 
immune system. These IELs are probably involved in local immune surveillance 
but their role in shaping immune system response in extra-intestinal sites (e.g. 
pancreas) is less clear. In this study we analyzed the cell-surface phenotypes of 
TCRγδ+ and TCR αβ+ T cells in NOD mice at different ages by flow cytometry.  
As in mice greater than 90% of IELs are CD8, we focused on TCRγδ+(CD8αα+) 
and TCRαβ+ (CD8αα+ and CD8αβ+) T cells. The expression of CD8 by most IELs 
also suggests that these cells recognize antigens presented by MHC class I 
molecules. 
First, we found that NOD IELs encompassed a high proportion of TCRγδ+ T 
cells. The TCRγδ+ population level is higher in the SI than in LI. The percentage 
of TCRγδ+ T cells increased during life in the epithelium of both SI and LI of 
NOD mice (FIG. 15). A vast majority of these TCRγδ+T cells express CD8α, but 
not CD8β (CD8αα homodimer) (data not shown). 
 Figure 15. TCRγδ+ IELs in SI and LI of NOD mice at different disease stages 
TCRγδ+ IELs are present in a higher proportion in the SI than in LI of NOD mice of different ages and 
disease stages (n = 3-5 per group). An increase of this cell population during development was found 
both in SI than LI. The evolution of this subset appeared complete at 8 weeks of age in SI of NOD 
mice, while in LI the development slightly increased with age. *p<0.05; **p<0.01 by non-parametric 
Mann–Whitney t test. 
PART IV : RESULTS 
 
76 
 
Although a considerable fraction of the intestinal IELs in NOD mice express a 
TCRγδ, we also find a high proportion of TCRαβ+ IELs in the intra-epithelial 
compartment of NOD mice . A similar amount of TCRαβ+ IELs are found in 
both SI and LI. While no age effect was found in LI, in SI an age trend is present 
and a significant difference was found among progressor and non progressors 
(FIG. 16). 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. TCRαβ+ IELs in SI and LI of NOD mice at different disease stages 
TCRαβ+ IELs are present in similar proportion between the SI and LI of NOD mice (n = 3-5). A higher 
proportion of TCRaβ+ IELs was found in SI in non-progressors compared to diabetic progressors. In LI 
this population appeared more stable during life. **p<0.01 by non-parametric Mann–Whitney t test. 
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CD8αβ+TCRαβ+ IELs are considered identical to conventional T cells in central 
lymphoid organs. Here we showed that frequencies of CD8αβ+TCRαβ+ IELs - 
CD8β chain is always expressed together with CD8α -appeared stable during 
life of NOD mice in both SI and LI (FIG. 17).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. TCRαβ+ CD8+IEL in SI and LI of NOD mice at different disease stages 
TCRαβ+ IELs are present in similar proportion between the SI than in LI of NOD mice (n = 3-5) and 
appear stable during life. *p<0.05; **p<0.01 by non-parametric Mann–Whitney t test. 
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Interestingly, a large number of CD8α+ T cells in the epithelium were negative 
for CD8β, suggesting that these cells express the CD8αα phenotype. These 
CD8αα+ T cells represented >80 and >50% of all the CD8+cells in the IELs of SI 
and LI respectively. CD8αα+TCRαβ+IELsremain an indefinable cell type, with 
their function and development understudied. CD8αα+TCRαβ+ IELs exhibit an 
‚activated although resting‛ phenotype and have been proposed to have a 
regulatory role within the intestine. Interestingly, in NOD mice, these 
CD8αα+TCRαβ+T cells accumulated with aging and were more present in the SI 
than in LI (FIG. 18). 
 
 
 
 
 
 
 
 
 
Figure 18. CD8αα+TCRαβ+ IELs in SI and LI of NOD mice at different disease stages 
CD8αα+TCRαβ+ IELs play a pivotal role in the maintenance of gut homeostasis. In NOD mice (n = 3-5), 
we found a higher proportion of CD8αα+TCRαβ+ IELs in SI than LI and we showed an age-dependent 
effect in their development. No significant differences were found between their frequencies in 
progressor and non-progressor populations *p<0.05; **p<0.01 by non-parametric Mann–Whitney t test. 
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Relatively minor populations of TCRαβ+ IELs are CD4 -CD8- (data not shown), 
CD4+(data not shown) or CD4+CD8αα+. Nevertheless, the CD4+CD8αα+TCRαβ+ 
IEL represents a newly characterized subset of cytotoxic T cells that questions 
our view of the strict dichotomy between CD4+ and CD8+ lineages. They are 
expressed in conditions of chronic viral infections but have also shown a 
protective role in the development of colitis in animal models128. In our study 
this population was virtually absent in the gut of 3-week-old NOD mice. 
Interestingly, in SI of NOD mice, this subset increased with age and was more 
abundant in non-progressor mice compared to diseased animals (progressors) 
(FIG. 19). 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. CD4+CD8αα+TCRαβ+IEL in SI and LI of NOD mice at different disease stages 
CD4+CD8αα+TCRαβ+ IELs are a newly characterized subset with intriguing characteristics. In NOD 
mice we found an increase of this population during life in both SI and LI. This population appeared 
much more represented in the SI. *p<0.05; **p<0.01 by non-parametric Mann–Whitney t test. 
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2.2 Characterization of LPL in NOD mice at different disease stages 
LPLs are in close contact with IELs to orchestrate the immune effector and 
regulatory responsesagainst luminal antigens and pathogens. In our study, we 
have further analyzed the lymphocyte populations from the outer intestinal 
compartment by flow cytometry. 
We found striking differences in the frequencies of LPLs of the SI and LI of 
NOD mice at different disease stages. A minor proportion of LPLs expressed 
TCRγδ in both SI and LI (FIG. 20), although there were more TCRγδ+ T cells in 
the SI than in the LI and their proportion increased with aging. Of interest, this 
population was more abundant in intestinal epithelium compared to LP.  
 
 
 
 
 
 
 
Figure 20. TCRγδ+ LPl in SI and LI of NOD mice at different disease stages 
TCRγδ+ LPLs were present in a higher proportion in the SI than in LI of NOD mice (n = 3-5). An 
increase during development was found both in SI than LI. The evolution of this subset appeared 
constant during life in both SI and LI. *p<0.05; **p<0.01 by non-parametric Mann–Whitney t test 
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In the LP of both intestinal segments many T cells expressed TCRαβ. In SI an 
age related increase is present while in LI  TCRαβ cells are higher in non-
progressors than progressor (FIG. 21).  
 
 
 
As for IEL we have focused our attention to CD8+ different subsets of LPL. 
TCRαβ CD8αα in LP are a less characterized population than their epithelial 
counterpart. In our mice we found that this population is more expressed in SI 
and they increase with age. (FIG. 22). 
 
Figure 21. TCRαβ+ LPLs in SI and LI of NOD mice at different disease stages 
TCRαβ+ LPLs are present in similar level between the SI and LI. In SI this population appeared 
enriching during life. In LI was not influenced by age but n higher proportion of TCRβ+ was found in non 
progressor mice. *p<0.05; **p<0.01 by non-parametric Mann–Whitney t test 
 
Figure 22. TCRαβ+ CD8αα+ LPL in SI and LI of NOD mice at different disease stages 
TCRαβ+ CD8αα+ T  cells in LP were present in a proportion comparable to epithelium .a higher 
proportion of TCRαβ+ CD8αα  in SI than LI  is present and an age related development is present. No 
significant difference was found in progressor and non progressor populations. *p<0.05; **p<0.01 by 
non-parametric Mann–Whitney t test 
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CD4+CD8αα+ are also present in LP in a lesser extent than in epithelium. Also in 
LP these population increases with age and is much more represented in the SI 
(FIG. 23). 
 
 
 
 
 
  
Figure 23. TCRαβ+ CD4+ CD8αα+ LPl in SI and LI of NOD mice at different disease stages 
TCRαβ+ CD4+ CD8αα+ LPLs were less represented than in the epithelium. These populations like their 
epithelial counterparts increased with age especially in the SI. *p<0.05; **p<0.01 by non-parametric 
Mann–Whitney t test 
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2.3 Characterization of regulatory T cells in lymphoid organs 
Tregs have a fundamental role in the maintenance of tolerance towards 
pancreatic islet antigens in NOD mice, as demonstrated by the worsening of 
diabetes after punctual ablation of this population and by their defective 
function in T1D patients28,29. For these reasons we characterized the evolution of 
this subset in MLNs, PLNs, PPs, and spleen during development and we looked 
for detectable differences in this population between progressor and non-
progressor mice. 
In the inner intestinal compartment (PP and MLN) of NOD mice, we found 
an age-dependent increase in CD4+CD25+Foxp3+ T cells. On the contrary, in the 
systemic compartment (spleen) the highest proportion of this Tregs were found 
at 3 weeks of age (FIG. 24). 
An interesting finding was the significant higher levels of 
CD4+CD25+Foxp3+Tregsin the PP and PLNs of non-progressors compared to 
disease animals (progressors).  
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Figure 24. CD4+CD25+FoxP3+Tregs in lymphoid organ of NOD mice during disease development 
An increase in the percentage of CD4+CD25+Foxp3+Tregs was found in the non-progressors’ PLN and PP 
of NOD mice (n = 3-5). This observation was not found in MLN and spleen. *p<0.05; **p<0.01 by non-
parametric Mann–Whitney t test. 
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Recently the gut is being increasingly acknowledged to play a role in the 
development of T1D. To test this hypothesis we have analyzed the gut 
permeability and intestinal lymphocytes subset in the epithelium and LP in the 
NOD mouse, the most widely studied animal model of autoimmune T1D, in 
different disease stages. 
Insulitis appeared as a common feature of our populations independently of 
the metabolic status of the animals, but increased in an age-dependent fashion. 
Our gut permeability study confirmed the findings of Lee et al.107that didn’t 
find significant differences between NOD mice of different ages. For the correct 
interpretation of this finding, it is necessary to evaluate gut permeability in 
congenic and controls strains of mice such as the C57BL/6 and the Non obese 
resistant (NOR) mouse to highlight the presence of an intrinsic intestinal barrier 
dysfunction in prediabetic NOD mice or a transient change before the onset of 
insulitis. The analysis of gut permeability in long time diabetic mice could 
exclude a role for hyperglycemia in the alteration of gut permeability. The high 
variability in Progressor mice and the relatively high level of permeability in 
Non Progressor could indicate a role for gut permeability in the onset of 
insulitis that is common to both population.  
IAA had higher level in the progressor population than progressor and 8W 
mice, the level of IAA however doesn’t correlate with the gravity of  
hyperglycemia (data not shown). This finding confirms the limited role of the 
antibody-mediated damage in the development of diabetes, despite the 
importance of B lymphocytes population in the onset of the disease. Such a role 
of b cells is testified by the partial success in preventing β-cell function decline 
of B-lymphocyte depletion therapy with the anti-CD20 Rituximab158.  
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These findings highlight the difficulty to find histological or immunologic 
marker that could foresee the development of frank diabetes and represent a 
present limit to our comprehension of the pathogenesis of the disease 
The role of regulatory population in preventing and halting the progression 
of T1D diabetes is well known. For this reason Foxp3+ Tregs were characterized 
in lymphoid tissues of NOD mice at different disease stages. We found an 
increase in Treg especially in PP and PLNs of Non-Progressor mice. The 
difference of age between Progressor and Non Progressor in the present study 
doesn’t allow us to exclude an age- related effect for this finding. An increase in 
T reg population with age, actually, has been recently documented in mice159. A 
perfect age-match between Progressor and Non Progressor could help 
understand the significance of the age as a confounding factor. If these findings 
were confirmed they will show an interesting link between intestinal GALT 
regulatory subsets and pancreatic immune system.  
This thesis represents the first longitudinal characterization of IEL and LPL 
in SI and LI in NOD mice. Such a systematic characterization has no clear 
precedent in literature: IEL have been more often characterized than LPL; CD8+ 
LPL are not commonly characterized, longitudinally study are usually limited 
to the neonatal and weaning period160–162, characterization is often limited to SI 
immune system163. We will therefore contextualize our findings in the context of 
this sometimes fragmentary literature.  
An age-related increase was found in different populations in our study 
namely TCRγδ+ IEL and LPL in both SI and LI, TCRαβ+ in LP of the SI, TCRαβ+ 
CD8αα+ and TCRαβ+ CD4+ CD8αα+ IEL and LPL in both SI and LI. We have 
documented an age development in these populations mostly between the 3 rd 
and 8th week without a decline due to aging. Studies on athymic mice have 
clarifiried that nIEL are already present at birth and decrease with age. The 
PART 5: DISCUSSION AND PERSPECTIVES 
 
88 
 
opposite phenomenon is thought to happen to iIEL127. Also LP lymphocytes 
show increase with age. The changing seen in our populations are therefore 
reasonably due to this process of progressive increase of iIELs and diminution 
of nIEL cells, and progressive colonization of the LP by peripheral lymphocytes. 
In C57/BL6 mice a study from Boll and colleagues164 found that γδ lineage is 
more frequent than αβ lineage in cells T cells of extrathymic origin colonizing 
the gut. These finding could be confirmed in our populations by the steady 
increase of TCRγδ population in confront to TCRαβ one in our study. The 
increase of CD8αα+ and TCRαβ+ CD4+ CD8αα+ IEL and LPL with aging have 
been already documented in a previous study165.  
As far as γδ+ and αβ+ subsets are concerned no clear difference between the 
ratio of these populations occurred in the different population studied (data not 
shown). We found an higher level of γδ lymphocytes in SI than LI, confirming a 
the finding by Beagley and colleagues166. Γδ+ lymphocytes could be therefore 
more involved in the development of tolerance toward food antigens that 
happens in the relatively sterile environment of SI, while αβ+ lymphocytes could 
help to cope with the bacterial antigen load present in LI. In our study, 
moreover, we found a statistical significant higher level of TCRαβ cells in non 
progressor than progressor in IEL small and LPL large, even if these trend is 
present also in the other populations without reaching statistical significance. 
These trend could be due to the higher age of the non progressor mice or to 
specific feature of microbiota in this population.  
LPL population shows an higher prevalence of CD4+ than CD8+ as found in 
previous studies127 CD8+ populations are less represented in LP then in 
epithelium, but show similar developmental trends.  
CD8αα is a homodymer expressed by multiple immune cell lineages. CD8αα 
lymphocytes show a regulatory function and the ability to preserve gut 
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homeostasis. In our study we characterized TCRγδ+ CD8 αα cells (data not 
shown), TCRαβ+  CD8 αα and the CD4 CTL population TCRαβ+  CD4+ CD8 αα+. 
We found an increase with age of all these population confirming the idea that 
gut environment promotes the expression of this receptor. TCRγδ+ CD8 αα+ 
lymphocytes showed similar levels in SI and LI, while TCRαβ+ CD8 αα and the 
CD4 CTL were less represented in the LI.  
To conclude we would like to highlight how this study stand as a pilot for 
further characterizations. An important limit of the present study is the small 
number of mice included in each experimental group. Thus, further 
experiments have been planned with larger groups of mice, including also other 
mice strains such as C57BL/6 and the NOR mouse to understand if NOD mice 
present innate alteration of gut immunity. Study of CD4+ lymphocytes subsets 
in LP such as Tregs and Th17 could deepen our understanding of intestinal 
lymphocytes population, especially in the LP. The study on microbial 
communities will complete the characterization of intestinal environment of our 
populations. The present study, moreover, will be the basis for future 
interventional study that will highlight the effect on intestinal immune system 
of procedure such as Vitamin D supplementation and induction of tolerance 
towards insulin antigens.  
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